DE69233697D1 - Verfahren zur Herstellung bindender Miniproteine - Google Patents

Verfahren zur Herstellung bindender Miniproteine

Info

Publication number
DE69233697D1
DE69233697D1 DE69233697T DE69233697T DE69233697D1 DE 69233697 D1 DE69233697 D1 DE 69233697D1 DE 69233697 T DE69233697 T DE 69233697T DE 69233697 T DE69233697 T DE 69233697T DE 69233697 D1 DE69233697 D1 DE 69233697D1
Authority
DE
Germany
Prior art keywords
display phage
relates
binding
miniproteins
display
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69233697T
Other languages
English (en)
Other versions
DE69233697T2 (de
Inventor
Robert Charles Ladner
Bruce Lindsay Roberts
Arthur Charles Ley
Rachel Baribault Kent
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dyax Corp
Original Assignee
Dyax Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24668274&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69233697(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US07/664,989 external-priority patent/US5223409A/en
Application filed by Dyax Corp filed Critical Dyax Corp
Application granted granted Critical
Publication of DE69233697D1 publication Critical patent/DE69233697D1/de
Publication of DE69233697T2 publication Critical patent/DE69233697T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43522—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from scorpions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C07K14/43572—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from bees
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/57—Compounds covalently linked to a(n inert) carrier molecule, e.g. conjugates, pro-fragrances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/14011—Details ssDNA Bacteriophages
    • C12N2795/14022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
DE69233697T 1991-03-01 1992-02-27 Verfahren zur Entwicklung von bindenden Mikroproteinen Expired - Lifetime DE69233697T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/664,989 US5223409A (en) 1988-09-02 1991-03-01 Directed evolution of novel binding proteins
US664989 2000-09-18

Publications (2)

Publication Number Publication Date
DE69233697D1 true DE69233697D1 (de) 2007-07-12
DE69233697T2 DE69233697T2 (de) 2008-01-24

Family

ID=24668274

Family Applications (4)

Application Number Title Priority Date Filing Date
DE69233697T Expired - Lifetime DE69233697T2 (de) 1991-03-01 1992-02-27 Verfahren zur Entwicklung von bindenden Mikroproteinen
DE69233769T Expired - Lifetime DE69233769D1 (de) 1991-03-01 1992-02-27 Chimäres Protein mit Mikroprotein mit zwei oder mehr Disulfidbindungen und Ausgestaltungen davon
DE69233795T Expired - Lifetime DE69233795D1 (de) 1991-03-01 1992-02-28 Verbesserter Epitop-präsentierender Phage
DE69233325T Expired - Lifetime DE69233325T2 (de) 1991-03-01 1992-02-28 Epitop praesentierender phage

Family Applications After (3)

Application Number Title Priority Date Filing Date
DE69233769T Expired - Lifetime DE69233769D1 (de) 1991-03-01 1992-02-27 Chimäres Protein mit Mikroprotein mit zwei oder mehr Disulfidbindungen und Ausgestaltungen davon
DE69233795T Expired - Lifetime DE69233795D1 (de) 1991-03-01 1992-02-28 Verbesserter Epitop-präsentierender Phage
DE69233325T Expired - Lifetime DE69233325T2 (de) 1991-03-01 1992-02-28 Epitop praesentierender phage

Country Status (10)

Country Link
US (1) US7893007B2 (de)
EP (6) EP1279731B1 (de)
JP (6) JP4146512B2 (de)
AT (4) ATE439435T1 (de)
AU (2) AU1545692A (de)
CA (2) CA2105300C (de)
DE (4) DE69233697T2 (de)
DK (4) DK1820858T3 (de)
ES (4) ES2287206T3 (de)
WO (2) WO1992015677A1 (de)

Families Citing this family (641)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US7413537B2 (en) 1989-09-01 2008-08-19 Dyax Corp. Directed evolution of disulfide-bonded micro-proteins
US5498538A (en) * 1990-02-15 1996-03-12 The University Of North Carolina At Chapel Hill Totally synthetic affinity reagents
US5747334A (en) * 1990-02-15 1998-05-05 The University Of North Carolina At Chapel Hill Random peptide library
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
DE69233697T2 (de) 1991-03-01 2008-01-24 Dyax Corp., Cambridge Verfahren zur Entwicklung von bindenden Mikroproteinen
US5733731A (en) * 1991-10-16 1998-03-31 Affymax Technologies N.V. Peptide library and screening method
US5270170A (en) * 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US6610656B1 (en) 1993-12-30 2003-08-26 President And Fellows Of Harvard College Method of promoting chondrocyte differentiation with hedgehog related polypeptides
US6261786B1 (en) 1993-12-30 2001-07-17 Imperial Cancer Res. Technology Screening assays for hedgehog agonists and antagonists
US6165747A (en) 1993-12-30 2000-12-26 President & Fellows Of Harvard College Nucleic acids encoding hedgehog proteins
US6384192B1 (en) 1993-12-30 2002-05-07 President & Fellows Of Harvard College Vertebrate embryonic pattern-inducing proteins
US7060450B1 (en) 1993-12-30 2006-06-13 President And Fellows Of Harvard College Screening assays for agonists and antagonists of the hedgehog signaling pathway
US6884775B1 (en) 1993-12-30 2005-04-26 President And Fellows Of Harvard College Methods and compositions for regulating skeletogenic formation
US20030186357A1 (en) 1993-12-30 2003-10-02 Philip W. Ingham Vertebrate embryonic pattern-inducing proteins, and uses related thereto
ATE300610T1 (de) 1994-01-31 2005-08-15 Univ Boston Bibliotheken aus polyklonalen antikörpern
US5565327A (en) * 1994-03-25 1996-10-15 Duke University Methods of diagnosing parasitic infections and of testing drug susceptibility of parasites
EP0699750A1 (de) * 1994-06-07 1996-03-06 Gesellschaft für biotechnologische Forschung mbH (GBF) Eine Sammling an Phagemiden, eine Sammling von Escherichia coli Zellen die diese Phagemide tragen, eine Sammling an Phagemid-Partikeln die daraus hergestellt würden und Phagemid-Partikel die durch dieses Verfahren erhalten würden
US6576236B1 (en) 1994-07-01 2003-06-10 Dana Farber Cancer Institute Methods for stimulating T cell responses by manipulating a common cytokine receptor γ chain
US5885577A (en) * 1994-09-21 1999-03-23 Cytogen Corporation Antigen binding peptides (abtides) from peptide libraries
CA2200684A1 (en) * 1994-09-21 1996-03-28 Cytogen Corporation Antigen binding peptides (abtides) from peptide libraries
US6475806B1 (en) 1995-06-07 2002-11-05 Praecis Pharmaceuticals, Inc. Anchor libraries and identification of peptide binding sequences
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
AU773394B2 (en) * 1996-10-08 2004-05-27 U-Bisys B.V. Methods and means for selecting peptides and proteins having specific affinity for a target
JP2001512560A (ja) * 1996-10-08 2001-08-21 ユー―ビスイス ベスローテン フェンノートシャップ 標的に対し特異的な親和性を有するペプチドおよびタンパク質の選択のための方法および手段
SE9700291D0 (sv) * 1997-01-31 1997-01-31 Pharmacia & Upjohn Ab Selection method and prodcts resulting therefrom
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
DE69837085T3 (de) 1997-04-16 2012-01-12 Millennium Pharmaceuticals, Inc. Crsp-proteine (cystein-reiche, sekretierte proteine), die dafür kodierenden nukleinsäuren und ihre verwendungen
AU8173098A (en) 1997-06-27 1999-01-19 Ontogeny, Inc. Neuroprotective methods and reagents
US7144997B2 (en) 1997-07-24 2006-12-05 Curis, Inc. Vertebrate embryonic patterning-inducing proteins, compositions and uses related therto
US6639051B2 (en) 1997-10-20 2003-10-28 Curis, Inc. Regulation of epithelial tissue by hedgehog-like polypeptides, and formulations and uses related thereto
US7163682B2 (en) 1998-04-13 2007-01-16 The Forsyth Institute Glucan binding protein and glucosyltransferase immunogens
US7056517B2 (en) 1998-04-13 2006-06-06 The Forsyth Institute Glucosyltransferase immunogens
WO1999058655A2 (en) * 1998-05-13 1999-11-18 Diversys Limited Phage display selection system for folded proteins
WO2000017336A1 (en) * 1998-09-19 2000-03-30 Sang Jun Lee Dna cassette encoding a multimer of a biologically active peptide and a cleavable linker attached thereto and process for preparing the biologically active peptide
US6420110B1 (en) 1998-10-19 2002-07-16 Gpc Biotech, Inc. Methods and reagents for isolating biologically active peptides
US6884770B1 (en) 1998-11-06 2005-04-26 Curis, Inc. Methods and compositions for treating or preventing peripheral neuropathies
NZ552959A (en) 1998-11-27 2008-06-30 Darwin Discovery Ltd Compositions and methods for increasing bone mineralization
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
ATE284415T1 (de) 1999-01-06 2004-12-15 Genentech Inc Mutierte variante des insulin-ähnlichen wachstumsfaktor-i (igf-i)
EP2301947A3 (de) 1999-02-26 2011-11-23 Millennium Pharmaceuticals, Inc. Sekretierte Proteine und Verwendungen dafür
CA2366559C (en) * 1999-03-23 2011-03-08 Biovation Limited Protein isolation and analysis
US6911429B2 (en) 1999-04-01 2005-06-28 Transition Therapeutics Inc. Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
DE19915057A1 (de) 1999-04-01 2000-10-19 Forschungszentrum Borstel Monoklonale Antikörper gegen das humane Mcm3 Protein, Verfahren zu ihrer Herstellung und ihre Verwendung
US6864235B1 (en) 1999-04-01 2005-03-08 Eva A. Turley Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
GB9908195D0 (en) 1999-04-09 1999-06-02 Microbiological Res Authority Treatment of intracellular infection
US7291714B1 (en) 1999-06-30 2007-11-06 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
US20040001826A1 (en) 1999-06-30 2004-01-01 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
WO2001014557A1 (en) 1999-08-23 2001-03-01 Dana-Farber Cancer Institute, Inc. Pd-1, a receptor for b7-4, and uses therefor
US8168178B2 (en) 1999-11-30 2012-05-01 Curis, Inc. Methods and compositions for regulating lymphocyte activity
US6951839B1 (en) 1999-11-30 2005-10-04 Curis, Inc. Methods and compositions for regulating lymphocyte activity
CA2396062C (en) 1999-12-30 2009-11-17 President And Fellows Of Harvard College Methods and compositions relating to modulation of hepatocyte growth, plasma cell differentiation or t cell subset activity by modulation of xbp-1 activity
EP2338515A3 (de) 2000-02-10 2011-11-16 Abbott Laboratories Humanes Interleukin-18 bindende Antikörper und Verfahren zu ihrer Herstellung und Verwendung
US7351540B1 (en) 2000-03-17 2008-04-01 Merck Patent Gmbh Protein isolation and analysis
DK1282437T3 (da) 2000-05-16 2008-06-30 Genentech Inc Behandling af brusklidelser
EP1714661A3 (de) 2000-05-19 2012-03-14 The Center for Blood Research, INC. Verfahren zur Diagnose und Behandlung von hämostatischen Störungen durch Modulation der P-Selectin Aktivität
EP2251026A1 (de) 2000-06-08 2010-11-17 Immune Disease Institute, Inc. Verfahren und Zusammensetzungen zur Hemmung der immunoglobulinvermittelten Reperfusionsverletzung
EP1326882A2 (de) 2000-06-19 2003-07-16 Dyax Corp. Enterokinase spaltungssequenze und deren verwendung
WO2002000692A2 (en) 2000-06-28 2002-01-03 Genetics Institute, Llc. Pd-l2 molecules: pd-1 ligands and uses therefor
DE60143986D1 (de) 2000-07-14 2011-03-17 Cropdesign Nv Inhibitoren für cyclin-dependent-kinase von pflanzen
CA2417432C (en) 2000-09-01 2010-11-02 The Center For Blood Research, Inc. Modified polypeptides stabilized in a desired conformation and methods for producing same
CA2427820A1 (en) 2000-11-01 2002-06-13 Elusys Therapeutics, Inc. Method of producing biospecific molecules by protein trans-splicing
EP1355939A2 (de) 2000-11-03 2003-10-29 Pestka Biomedical Laboratories, Inc. Interferone, deren verwendungen und zusammensetzungen
WO2002044419A2 (en) 2000-11-28 2002-06-06 Wyeth Expression analysis of kiaa nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
CA2429722A1 (en) 2000-11-28 2002-06-06 Wyeth Expression analysis of fkbp nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
US9249229B2 (en) 2000-12-08 2016-02-02 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US20060057651A1 (en) 2000-12-08 2006-03-16 Bowdish Katherine S Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US7408041B2 (en) 2000-12-08 2008-08-05 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
EP1341902A2 (de) 2000-12-08 2003-09-10 Alexion Pharmaceuticals, Inc. Chronische lymphozytäre leukämiezelllinie und deren verwendung zur herstellung eines antikörpers
CA2433800C (en) 2001-01-05 2016-09-13 Pfizer Inc. Antibodies to insulin-like growth factor i receptor
US7323327B2 (en) 2001-02-23 2008-01-29 Dsm Ip Assets B.V. Genes encoding novel proteolytic enzymes
ES2360205T3 (es) 2001-03-02 2011-06-01 Agennix Ag Sistema de ensayo de tres híbridos.
CA2440676A1 (en) 2001-03-22 2002-10-03 Abbott Gmbh & Co. Kg Transgenic animals expressing antibodies specific for genes of interest and uses thereof
EP2388590A1 (de) 2001-04-02 2011-11-23 Dana Farber Cancer Institute PD-1, ein Rezeptor für B7-4, und Verwendungen dafür
EP2278013A1 (de) 2001-04-16 2011-01-26 Wyeth Holdings Corporation Polypeptidantigene codierende offene Leseraster aus Streptococcus Pneumoniae und Verwendungen davon
WO2002090600A2 (en) 2001-05-08 2002-11-14 Darwin Molecular Corporation A method for regulating immune function in primates using the foxp3 protein
CA2385745C (en) 2001-06-08 2015-02-17 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
EP2270185A3 (de) 2001-06-22 2012-04-04 Pioneer Hi-Bred International, Inc. Defensinpolynucleotide und Verfahren zu ihrer Verwendung
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
US7175983B2 (en) 2001-11-02 2007-02-13 Abmaxis, Inc. Adapter-directed display systems
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
DE60234713D1 (de) 2001-12-18 2010-01-21 Endocube Sas Neue mit dem zelltod assoziierte proteine aus der thap familie und par4 verwandte signalwege, die bei der kontrolle von apoptosis involviert sind
US7858297B2 (en) 2001-12-18 2010-12-28 Centre National De La Recherche Scientifique Cnrs Chemokine-binding protein and methods of use
WO2003054155A2 (en) 2001-12-19 2003-07-03 Bristol-Myers Squibb Company Pichia pastoris formate dehydrogenase and uses therefor
JP2005531511A (ja) 2002-03-07 2005-10-20 ザ フォーシス インスティチュート グルカン結合タンパク質の免疫原性
US7745192B2 (en) 2002-04-03 2010-06-29 Venomics Pty Limited Prothrombin activating protein
US20030206898A1 (en) 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
ATE476500T1 (de) 2002-05-21 2010-08-15 Dsm Ip Assets Bv Neue phospholipasen und deren verwendungen
CN100480260C (zh) 2002-07-18 2009-04-22 克鲁塞尔荷兰公司 抗体混合物的重组生产
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
PL213925B1 (pl) 2002-07-19 2013-05-31 Abbott Biotech Ltd Przeciwcialo anty-TNFα lub jego czesc wiazaca antygen, ich zastosowanie oraz zestaw
US7250551B2 (en) 2002-07-24 2007-07-31 President And Fellows Of Harvard College Transgenic mice expressing inducible human p25
EA200500330A1 (ru) 2002-08-10 2006-06-30 Йейл Юниверсити Антагонисты nogo рецепторов
ES2527924T3 (es) 2002-08-19 2015-02-02 Dsm Ip Assets B.V. Nuevas lipasas y usos de las mismas
CN101044247B (zh) 2002-08-20 2011-06-22 千年药品公司 用于鉴定,评估,预防和治疗子宫颈癌的组合物,试剂盒及方法
WO2004018505A1 (en) 2002-08-20 2004-03-04 Yeda Research And Development Co. Ltd. Akap84 and its use for visualization of biological structures
JP2006502167A (ja) 2002-09-04 2006-01-19 バイオポリマー エンジニアリング，インコーポレイテッド 全グルカン粒子および抗体を用いた癌治療
AU2003300817A1 (en) 2002-11-21 2004-06-18 Celltech R And D, Inc. Modulating immune responses
JP2007524348A (ja) 2003-01-07 2007-08-30 ダイアックス、コープ クニッツドメインライブラリー
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US20040180387A1 (en) 2003-03-13 2004-09-16 Fujirebio Diagnostics, Inc. Detection of urinary mesothelin-/megakaryocyte potentiating factor-related peptides for assessment of ovarian cancer
US20050014932A1 (en) 2003-05-15 2005-01-20 Iogenetics, Llc Targeted biocides
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
WO2004106375A1 (en) 2003-05-30 2004-12-09 Merus Biopharmaceuticals B.V. I.O. Fab library for the preparation of anti vegf and anti rabies virus fabs
EP2508608A1 (de) 2003-06-09 2012-10-10 Alnylam Pharmaceuticals Inc. Verfahren zur Behandlung neurodegenerativer Erkrankungen
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
KR20060120652A (ko) 2003-10-07 2006-11-27 밀레니엄 파머슈티컬스 인코퍼레이티드 난소암의 확인, 평가, 예방 및 치료를 위한 핵산 분자 및단백질
US20050100965A1 (en) 2003-11-12 2005-05-12 Tariq Ghayur IL-18 binding proteins
JP4315982B2 (ja) 2004-01-09 2009-08-19 ファイザー インコーポレイティッド ＭＡｄＣＡＭに対する抗体
DK1737971T3 (da) 2004-01-20 2017-11-13 Merus Nv Blandinger af bindingsproteiner
EP1714151A4 (de) 2004-01-21 2009-06-10 Fujirebio America Inc Nachweis von mit mesothelin-/megakaryozyt-potenzierungsfaktor verwandten peptiden in peritonealflüssigkeit zur beurteilung des peritoneums und der peritonealhöhle
ATE498010T1 (de) 2004-03-01 2011-02-15 Immune Disease Inst Inc Natürliche igm-antikörper und inhibitoren davon
CN1957256B (zh) 2004-03-24 2013-01-02 三路影像公司 用于子宫颈疾病检测的方法和组合物
TWI439284B (zh) 2004-04-09 2014-06-01 Abbvie Biotechnology Ltd 用於治療ＴＮＦα相關失調症之多重可變劑量療法
AU2005250056A1 (en) 2004-06-03 2005-12-15 Athlomics Pty Ltd Agents and methods for diagnosing stress
GB0414054D0 (en) 2004-06-23 2004-07-28 Owen Mumford Ltd Improvements relating to automatic injection devices
BRPI0513200A (pt) 2004-07-16 2008-04-29 Pfizer Prod Inc uso de um anticorpo anti-igf-1r na preparação de um medicamento para tratamento combinado para malignidades não-hematológicas
US7342093B2 (en) 2004-07-23 2008-03-11 University Of Massachusetts Compounds that inhibit Hsp90 protein-protein interactions with IAP proteins
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
RS59399B1 (sr) 2005-03-23 2019-11-29 Genmab As Antitela protiv cd38 za lečenje multiplog mijeloma
AU2006239860B2 (en) 2005-04-25 2012-01-19 Amgen Fremont Inc. Antibodies to myostatin
CA2604357C (en) 2005-04-26 2012-01-17 Pfizer Inc. P-cadherin antibodies
US7595380B2 (en) 2005-04-27 2009-09-29 Tripath Imaging, Inc. Monoclonal antibodies and methods for their use in the detection of cervical disease
CA2903138A1 (en) 2005-05-16 2006-11-23 Abbvie Biotechnology Ltd. Use of tnfa inhibitor for treatment of erosive polyarthritis
US8124084B2 (en) 2005-05-17 2012-02-28 University Of Connecticut Compositions and methods for immunomodulation in an organism using IL-15 and soluble IL-15Ra
MEP35408A (en) 2005-05-27 2011-02-10 Biogen Idec Inc Tweak binding antibodies
WO2006138553A2 (en) 2005-06-17 2006-12-28 Wyeth Methods of purifying fc region containing proteins
JP5142458B2 (ja) 2005-06-30 2013-02-13 キヤノン株式会社 標的物質捕捉分子、標的物質捕捉用の素子、これらを用いた標的物質検出用の装置及びキット、並びに、標的物質の検出方法
CN101379085B (zh) 2005-06-30 2013-03-27 Abbvie公司 Il-12/p40结合蛋白
WO2007006091A1 (en) 2005-07-07 2007-01-18 Athlomics Pty Ltd Polynucleotide marker genes and their expression, for diagnosis of endotoxemia
GB2428293A (en) * 2005-07-13 2007-01-24 Domantis Ltd Phage display libraries
WO2007024715A2 (en) 2005-08-19 2007-03-01 Abbott Laboratories Dual variable domain immunoglobin and uses thereof
EP2500359A3 (de) 2005-08-19 2012-10-17 Abbott Laboratories Immunglobuline mit zweifacher variabler Domäne und ihre Verwendung
US20070041905A1 (en) 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EA201300320A1 (ru) 2005-09-07 2014-02-28 Эмджен Фримонт Инк. Моноклональные антитела человека к киназе-1, подобной рецептору активина
CA2624562A1 (en) 2005-09-30 2007-04-12 Abbott Gmbh & Co. Kg Binding domains of proteins of the repulsive guidance molecule (rgm) protein family and functional fragments thereof, and their use
ES2526705T3 (es) 2005-10-25 2015-01-14 The Johns Hopkins University Métodos y composiciones para el tratamiento de síndrome de Marfan y trastornos asociados
KR20140012160A (ko) 2005-11-01 2014-01-29 애브비 바이오테크놀로지 리미티드 바이오마커를 사용하여 강직성 척추염을 진단하기 위한 방법 및 조성물
US7807790B2 (en) 2005-11-14 2010-10-05 Metamol Theranostics, Llc Peptide sequence that promotes tumor invasion
CN103278647A (zh) 2005-11-30 2013-09-04 麻省理工学院 病原体检测生物传感器
KR20180058863A (ko) 2005-11-30 2018-06-01 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
US10183986B2 (en) 2005-12-15 2019-01-22 Industrial Technology Research Institute Trimeric collagen scaffold antibodies
US20070264687A1 (en) 2005-12-15 2007-11-15 Min-Yuan Chou Recombinant triplex scaffold-based polypeptides
US8014957B2 (en) 2005-12-15 2011-09-06 Fred Hutchinson Cancer Research Center Genes associated with progression and response in chronic myeloid leukemia and uses thereof
US7632498B2 (en) 2005-12-19 2009-12-15 Tripath Imaging, Inc. MCM6 and MCM7 monoclonal antibodies and methods for their use in the detection of cervical disease
EP1803814A1 (de) * 2005-12-27 2007-07-04 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Methode zur Verbesserung der Antikörperselektionskapazität in einer Phagen-Display-Bibliothek
RU2520088C2 (ru) 2006-01-12 2014-06-20 Алексион Фармасьютикалз, Инк. Антитела к ох-2/сd200 и их применение
WO2007090076A2 (en) 2006-01-27 2007-08-09 Tripath Imaging, Inc. Methods for identifying patients with an increased likelihood of having ovarian cancer and compositions therefor
EP1981902B1 (de) 2006-01-27 2015-07-29 Biogen MA Inc. Nogo-rezeptorantagonisten
TW200744634A (en) 2006-02-21 2007-12-16 Wyeth Corp Methods of using antibodies against human IL-22
TWI417301B (zh) 2006-02-21 2013-12-01 Wyeth Corp 對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途
WO2007111661A2 (en) 2006-03-20 2007-10-04 Xoma Technology Ltd. Human antibodies specific for gastrin materials and methods
KR20090005315A (ko) 2006-04-05 2009-01-13 애보트 바이오테크놀로지 리미티드 항체 정제
EP2666472A3 (de) 2006-04-10 2014-04-02 Abbott Biotechnology Ltd Anwendungen und Zusammensetzungen zur Behandlung von Psoriasis-Arthritis
EP2666479A3 (de) 2006-04-10 2014-03-26 Abbott Biotechnology Ltd Anwendungen und Zusammensetzungen zur Behandlung von juveniler rheumatoider Arthritis
CA2564435A1 (en) 2006-04-10 2007-10-10 Abbott Biotechnology Ltd. Methods for monitoring and treating intestinal disorders
US7702468B2 (en) 2006-05-03 2010-04-20 Population Diagnostics, Inc. Evaluating genetic disorders
US10522240B2 (en) 2006-05-03 2019-12-31 Population Bio, Inc. Evaluating genetic disorders
CN103316403B (zh) 2006-06-30 2017-05-24 艾伯维生物技术有限公司 自动注射装置
JP4546578B2 (ja) 2006-07-05 2010-09-15 カタリスト・バイオサイエンシーズ・インコーポレイテッド プロテアーゼスクリーニング方法およびそれにより同定されるプロテアーゼ
WO2008005529A2 (en) * 2006-07-07 2008-01-10 The Trustees Columbia University In The City Of New York Cell-mediated directed evolution
LT2511301T (lt) 2006-08-04 2018-04-10 Medimmune Limited Žmogaus antikūnas prieš erbb2
MY188368A (en) 2006-09-08 2021-12-06 Abbott Lab Interleukin-13 binding proteins
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
LT2081595T (lt) 2006-09-26 2019-07-10 Genmab A/S Anti-cd38 plius kortikosteroidai, plius nekortikosteroidinis chemoterapinis agentas, skirti vėžio gydymui
BRPI0719250A2 (pt) 2006-10-12 2015-06-16 Wyeth Corp Métodos e composições com opalescência reduzida.
ES2541546T3 (es) 2006-11-03 2015-07-21 Wyeth Llc Sustancias que inhiben la glucólisis en cultivo celular
JP2010510235A (ja) 2006-11-15 2010-04-02 ファンクショナル・ジェネティクス・インコーポレーテッド 抗ｔｓｇ１０１抗体およびウイルス感染の処置のためのその使用
US7488807B2 (en) 2006-11-22 2009-02-10 3M Innovative Properties Company Antibody with protein A selectivity
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008068780A2 (en) 2006-12-05 2008-06-12 Decode Genetics Ehf. Genetic markers for risk management of cardiac arrhythmia
EP3124045A3 (de) 2006-12-20 2017-05-03 Xoma (Us) Llc Behandlung von il-1-beta-bedingten erkrankungen
NZ704295A (en) 2006-12-27 2016-06-24 Harvard College Compositions and methods for the treatment of infections and tumors
NZ579401A (en) 2007-02-07 2012-03-30 Decode Genetics Ehf Genetic variants contributing to risk of prostate cancer
SG178811A1 (en) 2007-02-21 2012-03-29 Decode Genetics Ehf Genetic susceptibility variants associated with cardiovascular disease
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
JP4842400B2 (ja) 2007-03-22 2011-12-21 ヘプテアズ・セラピューティクス・リミテッド Ｇタンパク質共役型受容体変異体及びその選択方法
BRPI0809677A2 (pt) 2007-04-02 2014-10-07 Pfizer Anticorpos anti-ige
SI2147096T1 (sl) 2007-04-13 2015-07-31 Catalyst Biosciences, Inc., Modificirani polipeptidi faktorja VII in njihove uporabe
EP2535425A1 (de) 2007-05-25 2012-12-19 Decode Genetics EHF. Genetische varianten auf chr 10q26 als marker zur verwendung bei der risikobeurteilung, diagnose, prognose und behandlung von brustkrebs
US8999337B2 (en) 2007-06-11 2015-04-07 Abbvie Biotechnology Ltd. Methods for treating juvenile idiopathic arthritis by inhibition of TNFα
TWI478939B (zh) 2007-06-15 2015-04-01 Deutsches Krebsforsch 使用特定抗－ｌ１抗體治療腫瘤
EP2185593B1 (de) 2007-07-25 2017-12-13 Alexion Pharmaceuticals, Inc. Zusammensetzungen zur behandlung von autoimmunkrankheit
US8697360B2 (en) 2007-11-30 2014-04-15 Decode Genetics Ehf. Genetic variants on CHR 11Q and 6Q as markers for prostate and colorectal cancer predisposition
GB0724051D0 (en) 2007-12-08 2008-01-16 Medical Res Council Mutant proteins and methods for producing them
GB0724860D0 (en) 2007-12-20 2008-01-30 Heptares Therapeutics Ltd Screening
PL2391650T3 (pl) 2007-12-20 2015-03-31 Xoma Us Llc Sposoby leczenia dny
CA2710984C (en) 2007-12-28 2018-05-29 Elan Pharmaceuticals, Inc. Treatment and prophylaxis of amyloidosis
GB0802474D0 (en) 2008-02-11 2008-03-19 Heptares Therapeutics Ltd Mutant proteins and methods for selecting them
AU2009213689B2 (en) 2008-02-14 2014-11-20 Decode Genetics Ehf. Susceptibility variants for lung cancer
AU2009219358A1 (en) 2008-02-28 2009-09-03 3M Innovative Properties Company Antibodies to Clostridium difficile spores and uses thereof
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
WO2009109572A2 (en) * 2008-03-03 2009-09-11 Ablynx Nv Monovalent phage display of single variable domains
EP2274450A2 (de) 2008-04-01 2011-01-19 Decode Genetics EHF Suszeptibilitätsvarianten bei peripherer arterienkrankheit und bauchschlagader-aneurysma
KR101837329B1 (ko) 2008-04-25 2018-03-09 다이액스 코포레이션 Ｆｃｒｎ에 대한 항체 및 이들의 용도
EP2282769A4 (de) 2008-04-29 2012-04-25 Abbott Lab Dual-variable- domain-immunglobuline und ihre verwendungen
WO2009136382A2 (en) 2008-05-09 2009-11-12 Abbott Gmbh & Co. Kg Antibodies to receptor of advanced glycation end products (rage) and uses thereof
KR20110016959A (ko) 2008-06-03 2011-02-18 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
JP2011523853A (ja) 2008-06-03 2011-08-25 アボット・ラボラトリーズ 二重可変ドメイン免疫グロブリン及びその使用
US8951735B2 (en) 2008-07-07 2015-02-10 Decode Genetics Ehf. Genetic variants for breast cancer risk assessment
SG192489A1 (en) 2008-07-08 2013-08-30 Abbott Lab Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
RU2559525C2 (ru) 2008-07-08 2015-08-10 Эббви Инк Белки, связывающие простагландин е2, и их применение
NZ590605A (en) 2008-07-09 2012-11-30 Biogen Idec Inc Compositions comprising antibodies to lingo or fragments thereof
EP2342336B1 (de) 2008-09-05 2016-12-14 President and Fellows of Harvard College Kontinuierliche gerichtete evolution von proteinen und nukleinsäuren
US20100075329A1 (en) 2008-09-23 2010-03-25 O'toole Margot Methods for predicting production of activating signals by cross-linked binding proteins
CA2738019A1 (en) 2008-09-23 2010-04-08 President And Fellows Of Harvard College Sirt4 and uses thereof
CA2736904A1 (en) 2008-09-26 2010-04-01 Wyeth Llc Compatible display vector systems
KR102097887B1 (ko) 2008-09-26 2020-04-06 다나-파버 캔서 인스티튜트 인크. 인간 항-ｐｄ-１, ｐｄ-ｌ１, 및 ｐｄ-ｌ2 항체 및 그의 용도
ES2659875T3 (es) 2008-10-10 2018-03-19 Children's Medical Center Corporation Vacuna de trímero de Env VIH-1 bioquímicamente estabilizado
EP2349329A4 (de) 2008-10-14 2012-10-31 Dyax Corp Verwendung von igf-ii/igf-iie-bindung zur behandlung und prävention von systemischer sklerose im zusammenhang mit lungenfibrose
CN105111309A (zh) 2008-10-20 2015-12-02 Abbvie公司 使用a蛋白亲和层析分离和纯化抗体
WO2010051105A1 (en) 2008-10-29 2010-05-06 China Synthetic Rubber Corporation Methods and agents for the diagnosis and treatment of hepatocellular carcinoma
MX345226B (es) 2008-10-29 2017-01-20 Ablynx Nv Formulaciones de moleculas de union a antigeno de dominio sencillo.
MX2011004558A (es) 2008-10-29 2011-06-01 Wyeth Llc Procedimientos para la purificacion de moleculas de union a antigeno de un unico dominio.
CA2742802C (en) 2008-11-10 2019-11-26 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
RU2011121042A (ru) 2008-11-26 2013-01-10 Файв Прайм Терапеутикс, Инк. Композиции и способы регулирования экспрессии коллагена и актина гладких мышц посредством serpine2
AU2009319701B2 (en) 2008-11-28 2014-10-09 Dana-Farber Cancer Institute, Inc. Methods for the treatment of infections and tumors
CN102245771B (zh) 2008-12-16 2013-04-10 诺瓦提斯公司 酵母展示系统
WO2010080985A1 (en) 2009-01-08 2010-07-15 Dana-Farber Cancer Institute, Inc. Compositions and methods for induced brown fat differentiation
RU2011135768A (ru) 2009-01-29 2013-03-10 Эбботт Лэборетриз Белки, связывающие il-1
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
US8030026B2 (en) 2009-02-24 2011-10-04 Abbott Laboratories Antibodies to troponin I and methods of use thereof
PE20121094A1 (es) 2009-03-05 2012-09-13 Abbvie Inc Proteinas de union a il-17
US20100227335A1 (en) 2009-03-05 2010-09-09 Becton, Dickinson And Company Matrix metalloproteinase-7 (mmp-7) monoclonal antibodies and methods for their use in the detection of ovarian cancer
CA2753713A1 (en) 2009-03-06 2010-09-10 Tripath Imaging, Inc Glycodelin monoclonal antibodies and methods for their use in the detection of ovarian cancer
WO2010104114A1 (ja) * 2009-03-10 2010-09-16 独立行政法人産業技術総合研究所 ポリペプチドライブラリーを調製する方法
US8795963B2 (en) 2009-04-03 2014-08-05 Decode Genetics Ehf. Genetic markers for risk management of atrial fibrillation and stroke
ES2725356T3 (es) 2009-04-29 2019-09-23 Henry M Jackson Found Advancement Military Medicine Inc Anticuerpos monoclonales de ERG2 y su uso terapéutico
KR101721906B1 (ko) 2009-04-29 2017-03-31 애브비 바이오테크놀로지 리미티드 자동 주입 장치
CA2762837C (en) 2009-05-20 2021-08-03 Novimmune S.A. Synthetic polypeptide libraries and methods for generating naturally diversified polypeptide variants
RU2569187C2 (ru) 2009-05-29 2015-11-20 МорфоСис АГ Коллекция и способы ее применения
EP2261242A1 (de) 2009-06-10 2010-12-15 Universite Catholique De Louvain Aspartat-N-Acetyltransferaseenzym, Diagnoseverfahren und therapeutisches Verfahren
GB0910725D0 (en) 2009-06-22 2009-08-05 Heptares Therapeutics Ltd Mutant proteins and methods for producing them
EP2272979A1 (de) 2009-06-30 2011-01-12 Centre National de la Recherche Scientifique (CNRS) Verfahren zum Testen einer Person, die eine Prädisposition für Krebs aufzuweisen scheint
CN102481380A (zh) 2009-07-09 2012-05-30 霍夫曼-拉罗奇有限公司 体内肿瘤血管系统成像
AU2010269841A1 (en) 2009-07-10 2012-02-23 Decode Genetics Ehf Genetic markers associated with risk of diabetes mellitus
WO2011014771A1 (en) 2009-07-31 2011-02-03 Wayne State University Monophosphorylated lipid a derivatives
US9259476B2 (en) 2009-07-31 2016-02-16 Wayne State University Monophosphorylated lipid A derivatives
EP2470568A2 (de) 2009-08-29 2012-07-04 Abbott Laboratories Therapeutische dll4-bindende proteine
SG178602A1 (en) 2009-09-01 2012-04-27 Abbott Lab Dual variable domain immunoglobulins and uses thereof
US20110189183A1 (en) 2009-09-18 2011-08-04 Robert Anthony Williamson Antibodies against candida, collections thereof and methods of use
JP5885664B2 (ja) 2009-09-25 2016-03-15 ゾーマ テクノロジー リミテッド スクリーニング法
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
US9175070B2 (en) 2009-09-25 2015-11-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to HIV-1 and their use
EP2483407A2 (de) 2009-09-30 2012-08-08 President and Fellows of Harvard College Verfahren zur autophagie-modulation durch modulation autophagie-verstärkender genprodukte
BR112012008833A2 (pt) 2009-10-15 2015-09-08 Abbott Lab imunoglobulinas de dominio variavel duplo e usos das mesmas
RS60577B1 (sr) 2009-10-20 2020-08-31 Abbvie Inc Izolacija i prečišćavanje anti-il-13 antitela upotrebom protein a afinitetne hromatografije
US20110098862A1 (en) 2009-10-27 2011-04-28 ExxonMobil Research Engineering Company Law Department Multi-stage processes and control thereof
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2011053707A1 (en) 2009-10-31 2011-05-05 Abbott Laboratories Antibodies to receptor for advanced glycation end products (rage) and uses thereof
EP2499491B1 (de) 2009-11-11 2015-04-01 Gentian AS Immunassay zur untersuchung von assoziierten analyten unterschiedlichen ursprungs
WO2011060272A2 (en) 2009-11-13 2011-05-19 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1
CA2780069C (en) 2009-12-08 2018-07-17 Abbott Gmbh & Co. Kg Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration
DK2516702T3 (en) 2009-12-23 2018-04-30 Affinity Biosciences Pty Ltd PROTEIN DISPLAY
ES2688093T3 (es) 2010-01-06 2018-10-30 Dyax Corp. Proteínas de unión a calicreína plasmática
KR20130005264A (ko) 2010-01-11 2013-01-15 알렉시온 파마슈티칼스, 인코포레이티드 항-ｃｄ200 항체들로 치료한 사람에게서 면역조절 효과의 생체지표들
US9745589B2 (en) 2010-01-14 2017-08-29 Cornell University Methods for modulating skeletal remodeling and patterning by modulating SHN2 activity, SHN3 activity, or SHN2 and SHN3 activity in combination
US10429384B2 (en) 2010-01-22 2019-10-01 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of metabolic disorders
JP2013518590A (ja) 2010-02-02 2013-05-23 アボツト・バイオテクノロジー・リミテツド ＴＮＦ−α阻害剤を用いる処置に対する応答性を予測するための方法および組成物
TWI518325B (zh) 2010-02-04 2016-01-21 自治醫科大學 對ａｌｋ抑制劑具有先抗性或後抗性癌症的識別、判斷和治療
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
SG10201501562VA (en) 2010-03-02 2015-04-29 Abbvie Inc Therapeutic dll4 binding proteins
EP4012714A1 (de) 2010-03-23 2022-06-15 Iogenetics, LLC. Bioinformatikverfahren zur bestimmung von peptidbindungen
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
UY33386A (es) 2010-05-14 2011-12-30 Abbott Laboratoires Proteínas de unión a il-1
DK2575884T3 (en) 2010-06-03 2018-09-03 Abbvie Biotechnology Ltd APPLICATIONS AND COMPOSITIONS TO TREAT HIDRADENITIS SUPPURATIVA (HS)
TW201207383A (en) 2010-06-16 2012-02-16 Abbott Lab Comparison of protein samples
US9405884B2 (en) 2010-06-16 2016-08-02 Abbvie Inc. Methods and systems for the analysis of protein samples
US20120009196A1 (en) 2010-07-08 2012-01-12 Abbott Laboratories Monoclonal antibodies against hepatitis c virus core protein
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2012007880A2 (en) 2010-07-16 2012-01-19 Ablynx Nv Modified single domain antigen binding molecules and uses thereof
DK2601609T3 (en) 2010-08-02 2017-06-06 Population Bio Inc COMPOSITIONS AND METHODS FOR DISCOVERING MUTATIONS CAUSING GENETIC DISORDERS
MX341579B (es) 2010-08-03 2016-08-25 Abbvie Inc * Inmunoglobulinas de dominio variable doble y usos de las mismas.
WO2012019061A2 (en) 2010-08-05 2012-02-09 Stem Centrx, Inc. Novel effectors and methods of use
EP2420250A1 (de) 2010-08-13 2012-02-22 Universitätsklinikum Münster Anti-Syndecan-4-Antikörper
CN103298833B (zh) 2010-08-14 2015-12-16 Abbvie公司 β淀粉样蛋白结合蛋白
PL3333188T3 (pl) 2010-08-19 2022-05-09 Zoetis Belgium S.A. Przeciwciała anty-ngf i ich zastosowanie
AU2011293253B2 (en) 2010-08-26 2014-12-11 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
PE20140190A1 (es) 2010-08-27 2014-02-10 Stem Centrx Inc Moduladores de proteinas notum y metodos de uso
US9458231B2 (en) 2010-09-03 2016-10-04 Stemcentrx, Inc. Modulators and methods of use
SG188616A1 (en) 2010-09-20 2013-04-30 Abbvie Inc Purification of antibodies using simulated moving bed chromatography
WO2012044921A1 (en) 2010-10-01 2012-04-05 St. Jude Children's Research Hospital Methods and compositions for typing molecular subgroups of medulloblastoma
WO2012052391A1 (en) 2010-10-19 2012-04-26 Glaxo Group Limited Polypeptide with jmjd3 catalytic activity
US9072766B2 (en) 2010-11-18 2015-07-07 Beth Israel Deaconess Medical Center, Inc. Methods of treating obesity by inhibiting nicotinamide N-methyl transferase (NNMT)
US8728981B2 (en) 2010-11-19 2014-05-20 Morphosys Ag Collection and methods for its use
EP2648748A1 (de) 2010-12-08 2013-10-16 Stem Centrx, Inc. Neuartige modulatoren und verfahren zu ihrer verwendung
WO2012121775A2 (en) 2010-12-21 2012-09-13 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
TW201307388A (zh) 2010-12-21 2013-02-16 Abbott Lab Ｉｌ－１結合蛋白
JP6088438B2 (ja) 2010-12-22 2017-03-01 プレジデント アンド フェローズ オブ ハーバード カレッジ 連続的定向進化
US20140038842A1 (en) 2010-12-28 2014-02-06 Xoma Technology Cell surface display using pdz domains
WO2012089814A1 (en) 2010-12-30 2012-07-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Antigen binding formats for use in therapeutic treatments or diagnostic assays
EP2667918B1 (de) 2011-01-24 2017-03-01 AbbVie Biotechnology Ltd Automatische injektionsvorrichtungen mit übersrpitzten griffflächen
AU2012212066A1 (en) 2011-02-03 2013-08-15 Alexion Pharmaceuticals, Inc. Use of an anti-CD200 antibody for prolonging the survival of allografts
US9956236B2 (en) 2011-02-07 2018-05-01 Cornell University Methods for increasing immune responses using agents that directly bind to and activate IRE-1
SA112330278B1 (ar) 2011-02-18 2015-10-09 ستيم سينتركس، انك. مواد ضابطة جديدة وطرق للاستخدام
PE20180776A1 (es) 2011-03-02 2018-05-07 Berg Llc Ensayos interrogatorios basados en celulas y usos de los mismos
WO2012122219A2 (en) 2011-03-07 2012-09-13 University Of Louisville Research Foundation Predictive marker of dnmt1 inhibitor therapeutic efficacy and methods of using the marker
WO2012125735A1 (en) 2011-03-15 2012-09-20 Abott Laboratories An integrated approach to the isolation and purification of antibodies
JP6130350B2 (ja) 2011-03-30 2017-05-17 アブリンクス エン．ヴェー． ＴＮＦαに対する単一ドメイン抗体で免疫障害を処置する方法
CA2831247C (en) 2011-03-31 2020-07-21 Oriental Yeast Co., Ltd. Cancer immunopotentiating agent containing rankl antagonist
WO2012134813A1 (en) 2011-03-31 2012-10-04 St. Jude Children's Research Hospital Methods and compositions for identifying minimal residual disease in acute lymphoblastic leukemia
JP2014513289A (ja) 2011-04-08 2014-05-29 バイオジェン・アイデック・エムエイ・インコーポレイテッド ＩＦＮβに対する治療応答性を予測するバイオマーカーおよびその使用
US9150644B2 (en) 2011-04-12 2015-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
CA2837527C (en) 2011-06-02 2019-05-28 Dyax Corp. Fc receptor binding proteins
SI2714735T1 (sl) 2011-06-03 2021-12-31 Xoma Technology Ltd. Protitelesa, specifična za TGF-beta
ES2609313T3 (es) 2011-06-29 2017-04-19 Affinity Biosciences Pty Ltd Método de expresión de proteínas
KR20140061403A (ko) 2011-07-13 2014-05-21 애브비 인코포레이티드 항―ｉｌ―１３ 항체를 이용하여 천식을 치료하기 위한 방법 및 조성물
EP2748192B2 (de) 2011-08-23 2022-04-20 Foundation Medicine, Inc. Kif5b-re-fusionsmoleküle und verwendungen davon
US20130058947A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc Novel Modulators and Methods of Use
US10093705B2 (en) 2011-09-13 2018-10-09 Dana-Farber Cancer Institute, Inc. Compositions and methods for brown fat induction and activity using FNDC5
EP2771349B1 (de) 2011-09-16 2020-02-26 Iogenetics, LLC. Bioinformatikverfahren zur bestimmung von peptidbindungen
EP2766483B1 (de) 2011-10-10 2022-03-23 The Hospital For Sick Children Verfahren und zusammensetzungen zum screening und zur behandlung von entwicklungsstörungen
WO2013063095A1 (en) 2011-10-24 2013-05-02 Abbvie Inc. Immunobinders directed against sclerostin
IN2014CN03936A (de) 2011-10-24 2015-09-04 Abbvie Inc
WO2013067268A1 (en) 2011-11-03 2013-05-10 Tripath Imaging, Inc. Methods and compositions for preparing samples for immunostaining
EP2773779B1 (de) 2011-11-04 2020-10-14 Population Bio, Inc. Verfahren und zusammensetzungen zur diagnose, prognose und behandlung neurologischer erkrankungen
MX2014005570A (es) 2011-11-08 2014-05-30 Pfizer El uso de anticuerpos anti factor estimulante de la colonia de macrofagos para tratar trastornos inflamatorios.
US20140017174A1 (en) 2011-11-30 2014-01-16 Raja Atreya Methods and compositions for determining responsiveness to treatment with a tnf-alpha inhibitor
WO2013090635A2 (en) 2011-12-14 2013-06-20 AbbVie Deutschland GmbH & Co. KG Composition and method for the diagnosis and treatment of iron-related disorders
WO2013090633A2 (en) 2011-12-14 2013-06-20 AbbVie Deutschland GmbH & Co. KG Composition and method for the diagnosis and treatment of iron-related disorders
CN104144946A (zh) 2011-12-19 2014-11-12 爱克索马美国有限责任公司 治疗痤疮的方法
CA2861610A1 (en) 2011-12-30 2013-07-04 Abbvie Inc. Dual specific binding proteins directed against il-13 and/or il-17
NZ625403A (en) 2012-01-27 2016-03-31 Abbvie Inc Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
CA2863887C (en) 2012-02-09 2023-01-03 Population Diagnostics, Inc. Methods of screening low frequency gdna variation biomarkers for pervasive developmental disorder (pdd) or pervasive developmental disorder - not otherwise specified (pdd_nos)
BR112014020826A8 (pt) 2012-02-24 2017-09-19 Stem Centrx Inc Anticorpo que se liga especificamente a um epítopo, ácido nucleico, vetor ou célula hospedeira, conjugado de fármaco – anticorpo, composição farmacêutica compreendendo o referido anticorpo, uso do mesmo, kit e método de preparação do conjugado
EP2834366A4 (de) 2012-04-02 2016-04-27 Berg Llc Auf abfragezellen basierende assays und verwendungen davon
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
NZ772318A (en) 2012-04-20 2023-06-30 Merus Nv Methods and means for the production of ig-like molecules
WO2013158275A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Cell culture methods to reduce acidic species
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9169304B2 (en) 2012-05-01 2015-10-27 Pfenex Inc. Process for purifying recombinant Plasmodium falciparum circumsporozoite protein
WO2013173364A2 (en) 2012-05-14 2013-11-21 Biogen Idec Ma Inc. Lingo-2 antagonists for treatment of conditions involving motor neurons
US20130336957A1 (en) 2012-05-21 2013-12-19 Abbvie, Inc. Novel purification of human, humanized, or chimeric antibodies using protein a affinity chromatography
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
JP6629069B2 (ja) 2012-06-06 2020-01-15 ゾエティス・エルエルシー イヌ化抗ｎｇｆ抗体およびその方法
BR112014032916A2 (pt) 2012-06-28 2017-08-01 Pfizer anticorpos anti-fármacos e usos destes para o monitoramento de fármaco
UY34905A (es) 2012-07-12 2014-01-31 Abbvie Inc Proteínas de unión a il-1
ES2771324T3 (es) 2012-08-03 2020-07-06 Dana Farber Cancer Inst Inc Usos médicos de agentes que modulan la activación de las células inmunitarias y métodos de detección correspondientes
TW201410709A (zh) 2012-08-08 2014-03-16 Daiichi Sankyo Co Ltd 肽庫及其利用
US9737493B2 (en) 2012-09-07 2017-08-22 University Of Louisville Research Foundation, Inc. Compositions and methods for modulating DNMT1 inhibitor activity
WO2014043519A1 (en) 2012-09-14 2014-03-20 Population Diagnostics Inc. Methods and compositions for diagnosing, prognosing, and treating neurological conditions
WO2014052855A1 (en) 2012-09-27 2014-04-03 Population Diagnostics, Inc. Methods and compositions for screening and treating developmental disorders
KR20210063443A (ko) 2012-10-09 2021-06-01 바이오젠 엠에이 인코포레이티드 탈수초성 질환의 치료를 위한 복합 요법 및 용도
TW202210507A (zh) 2012-11-01 2022-03-16 美商艾伯維有限公司 抗-vegf/dll4雙重可變區域免疫球蛋白及其用途
CA2890207A1 (en) 2012-11-05 2014-05-08 Foundation Medicine, Inc. Novel ntrk1 fusion molecules and uses thereof
SG11201502876RA (en) 2012-11-08 2015-06-29 Eleven Biotherapeutics Inc Il-6 antagonists and uses thereof
WO2014074942A1 (en) 2012-11-08 2014-05-15 Illumina, Inc. Risk variants of alzheimer's disease
EA034757B1 (ru) 2012-12-10 2020-03-17 Байоджен Ма Инк. Антитела против антигена 2 дендритных клеток крови и их применение
KR101600902B1 (ko) * 2012-12-11 2016-03-10 주식회사 셀레믹스 코돈 조합화 및 변이유발을 이용한 유전자 라이브러리의 합성 방법
WO2014100542A1 (en) 2012-12-21 2014-06-26 Abbvie, Inc. High-throughput antibody humanization
US10717965B2 (en) 2013-01-10 2020-07-21 Gloriana Therapeutics, Inc. Mammalian cell culture-produced neublastin antibodies
EP2945652B1 (de) 2013-01-18 2021-07-07 Foundation Medicine, Inc. Verfahren zur behandlung cholangiokarzinom
US9593339B1 (en) 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
RS58873B1 (sr) 2013-02-22 2019-08-30 Abbvie Stemcentrx Llc Antidll3-antitelo-pbd konjugati i njihova upotreba
CA2899308C (en) 2013-03-14 2017-04-18 Abbvie Inc. Low acidic species adalimumab compositions and uses thereof
WO2014153056A2 (en) 2013-03-14 2014-09-25 Parkash Gill Cancer treatment using antibodies that bing cell surface grp78
CA2906417C (en) 2013-03-14 2022-06-21 Robert Ziemann Hcv core lipid binding domain monoclonal antibodies
BR112015023239A8 (pt) 2013-03-14 2018-04-17 Abbott Lab ensaio de combinação de anticorpo-antígeno de hcv e métodos e composições para uso do mesmo
CA2899449A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. Low acidic species compositions and methods for producing the same using displacement chromatography
WO2014143342A1 (en) 2013-03-14 2014-09-18 Abbott Laboratories Hcv ns3 recombinant antigens and mutants thereof for improved antibody detection
WO2014142882A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Protein purification using displacement chromatography
EP4079760A3 (de) 2013-03-15 2023-01-25 Sanofi Pasteur Inc. Antikörper gegen clostridium-difficile-toxine und verfahren zur verwendung davon
CN105392801A (zh) 2013-03-15 2016-03-09 比奥根Ma公司 使用抗αvβ5抗体治疗和预防急性肾损伤
US9062108B2 (en) 2013-03-15 2015-06-23 Abbvie Inc. Dual specific binding proteins directed against IL-1 and/or IL-17
US9469686B2 (en) 2013-03-15 2016-10-18 Abbott Laboratories Anti-GP73 monoclonal antibodies and methods of obtaining the same
WO2014168933A1 (en) 2013-04-08 2014-10-16 Cytodyn Inc. Felinized antibodies and methods of treating retroviral infections in felines
AU2014275166B2 (en) 2013-06-06 2020-09-10 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment prevention, and treatment of cancer using PD-L1 isoforms
ES2753419T3 (es) 2013-06-07 2020-04-08 Univ Duke Inhibidores del factor H del complemento
WO2015017529A2 (en) 2013-07-31 2015-02-05 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating thermogenesis using pth-related and egf-related molecules
WO2015026846A1 (en) 2013-08-19 2015-02-26 Biogen Idec Ma Inc. Control of protein glycosylation by culture medium supplementation and cell culture process parameters
EP3338793A1 (de) 2013-08-28 2018-06-27 AbbVie Stemcentrx LLC Neuartige sez6-modulatoren und verfahren zur verwendung
ES2871418T3 (es) 2013-08-28 2021-10-28 Abbvie Stemcentrx Llc Composiciones y métodos de conjugación de anticuerpos específicos de sitio
US10611794B2 (en) 2013-09-25 2020-04-07 Bioverativ Therapeutics Inc. On-column viral inactivation methods
EP3049521B1 (de) 2013-09-25 2019-03-06 Cornell University Verbindungen zur induzierung von antitumorimmunität und verfahren dafür
EP3757130A1 (de) 2013-09-26 2020-12-30 Costim Pharmaceuticals Inc. Verfahren zur behandlung von blutkrebs
WO2015057939A1 (en) 2013-10-18 2015-04-23 Biogen Idec Ma Inc. Anti-s1p4 antibodies and uses thereof
US10980896B2 (en) 2013-10-29 2021-04-20 President And Fellows Of Harvard College Methods and compositions for inhibiting oxidative stress
US20160272673A1 (en) 2013-11-07 2016-09-22 Abbvie Inc. Isolation and purification of dvd-igs
DK3511422T3 (da) 2013-11-12 2023-02-06 Population Bio Inc Fremgangsmåder og sammensætninger til diagnosticering, prognose og behandling af endometriose
CN105940115B (zh) 2013-11-15 2021-07-06 巴斯德研究所 恶性疟原虫青蒿素耐药性的分子标记物
EP3083964B1 (de) 2013-12-19 2022-01-26 Novartis AG Menschliche chimäre mesothelin-antigenrezeptoren und verwendungen davon
WO2015095868A1 (en) 2013-12-20 2015-06-25 Wake Forest University Health Sciences Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
JP2017500017A (ja) 2013-12-20 2017-01-05 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 生物薬剤フェドバッチ生産能力及び生産物品質を改善するための灌流シード培養の使用
EP2960252A1 (de) 2014-06-26 2015-12-30 Institut Pasteur Phospholipase zur Behandlung von Immunosuppression
WO2015175340A1 (en) 2014-05-13 2015-11-19 Bavarian Nordic, Inc. Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and a monoclonal antibody against tim-3
WO2015134121A2 (en) 2014-01-20 2015-09-11 President And Fellows Of Harvard College Negative selection and stringency modulation in continuous evolution systems
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
KR102356951B1 (ko) 2014-02-11 2022-01-27 비스테라, 인크. 뎅기열 바이러스에 대한 항체 분자 및 그의 용도
AU2015218633A1 (en) 2014-02-21 2016-09-01 Abbvie Stemcentrx Llc Anti-DLL3 antibodies and drug conjugates for use in melanoma
KR102442436B1 (ko) 2014-03-14 2022-09-15 노파르티스 아게 Lag-3에 대한 항체 분자 및 그의 용도
WO2015148515A1 (en) 2014-03-24 2015-10-01 Biogen Ma Inc. Methods for overcoming glutamine deprivation during mammalian cell culture
EP3154584B1 (de) 2014-06-03 2021-08-04 XBiotech Inc. Zusammensetzungen und verfahren zur behandlung und verhinderung von staphylococcus-aureus-behandlungen
US10626375B2 (en) 2014-06-25 2020-04-21 Auxergen, Inc. Disease control of the plant bacterial pathogens causing citrus canker and rice blight
TWI719942B (zh) 2014-07-21 2021-03-01 瑞士商諾華公司 使用ｃｄ３３嵌合抗原受體治療癌症
CN113846062A (zh) 2014-07-25 2021-12-28 赛拉福柯蒂斯公司 用于嵌合抗原受体分子的调控表达的慢病毒载体
WO2016025880A1 (en) 2014-08-14 2016-02-18 Novartis Ag Treatment of cancer using gfr alpha-4 chimeric antigen receptor
CN112410363A (zh) 2014-08-19 2021-02-26 诺华股份有限公司 抗cd123嵌合抗原受体(car)用于癌症治疗
WO2016036403A1 (en) 2014-09-05 2016-03-10 Population Diagnostics Inc. Methods and compositions for inhibiting and treating neurological conditions
US11344620B2 (en) 2014-09-13 2022-05-31 Novartis Ag Combination therapies
WO2016042412A1 (en) 2014-09-16 2016-03-24 Symphogen A/S Anti-met antibodies and compositions
KR102554634B1 (ko) 2014-09-30 2023-07-11 도이체스크레브스포르슝스젠트룸스티프퉁데스외펜트리헨레크츠 L1cam에 결합하는 신규한 결합 분자 특히 항체(cd171)
WO2016054555A2 (en) 2014-10-03 2016-04-07 Novartis Ag Combination therapies
AU2015333687B2 (en) 2014-10-14 2021-03-18 Dana-Farber Cancer Institute, Inc. Antibody molecules to PD-L1 and uses thereof
MA41685A (fr) 2014-10-17 2017-08-22 Biogen Ma Inc Supplémentation en cuivre pour la régulation de la glycosylation dans un procédé de culture cellulaire de mammifère
US10920208B2 (en) 2014-10-22 2021-02-16 President And Fellows Of Harvard College Evolution of proteases
MA40864A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
BR112017009297B1 (pt) 2014-11-05 2024-02-15 Annexon, Inc Anticorpos antifator de complemento c1q humanizados, composição farmacêutica e kit compreendendo os mesmos, uso terapêutico destes,polinucleotídeo isolado, célula hospedeira isolada, bem como métodos in vitro para detectar sinapses
PE20171107A1 (es) 2014-11-07 2017-08-07 Eleven Biotherapeutics Inc Anticuerpos mejorados contra il-6
WO2016073894A1 (en) 2014-11-07 2016-05-12 Eleven Biotherapeutics, Inc. Therapeutic agents with increased ocular retention
EP3220900B1 (de) 2014-11-21 2020-09-23 University of Maryland, Baltimore Systeme zur gezielten strukturspezifischen partikelabgabe
AU2015360903B2 (en) 2014-12-08 2021-03-25 Dana-Farber Cancer Institute, Inc. Methods for upregulating immune responses using combinations of anti-RGMB and anti-PD-1 agents
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
EP3233918A1 (de) 2014-12-19 2017-10-25 Novartis AG Kombinationstherapien
JP2018504400A (ja) 2015-01-08 2018-02-15 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． Ｌｉｎｇｏ‐１拮抗薬及び脱髄障害の治療のための使用
EP3265491A1 (de) 2015-03-03 2018-01-10 Xoma (Us) Llc Behandlung von postprandialer hyperinsulinämie und hyperglykämie nach bariatrischer chirurgie
EP3735982A1 (de) 2015-03-10 2020-11-11 The University of Massachusetts Abzielung auf gdf6 und bmp-signalisierung für antimelanomtherapie
EP3277716B1 (de) 2015-04-03 2020-06-24 XOMA Technology Ltd. Behandlung von krebs unter verwendung von inhibitoren von tgf-beta und pd-1
US11299729B2 (en) 2015-04-17 2022-04-12 President And Fellows Of Harvard College Vector-based mutagenesis system
EP3285811A1 (de) 2015-04-21 2018-02-28 Institut Gustave Roussy Therapeutische verfahren, produkte und zusammensetzungen zur hemmung von znf555
EP3736287A1 (de) 2015-05-11 2020-11-11 The Johns Hopkins University Autoimmunantikörper zur verwendung in der hemmung des krebszellenwachstums
EP3303395B1 (de) 2015-05-29 2019-12-11 AbbVie Inc. Anti-cd40-antikörper und verwendungen davon
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
US10392674B2 (en) 2015-07-22 2019-08-27 President And Fellows Of Harvard College Evolution of site-specific recombinases
WO2017015559A2 (en) 2015-07-23 2017-01-26 President And Fellows Of Harvard College Evolution of bt toxins
WO2017019897A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3
PT3317301T (pt) 2015-07-29 2021-07-09 Novartis Ag Terapias de associação compreendendo moléculas de anticorpo contra lag-3
US10612011B2 (en) 2015-07-30 2020-04-07 President And Fellows Of Harvard College Evolution of TALENs
AU2016304588A1 (en) 2015-08-06 2018-02-15 Xoma (Us) Llc Antibody fragments against the insulin receptor and uses thereof to treat hypoglycemia
WO2017040342A1 (en) 2015-08-28 2017-03-09 Genentech, Inc. Anti-hypusine antibodies and uses thereof
PT3350220T (pt) 2015-09-15 2021-08-06 Scholar Rock Inc Anticorpos anti-pró-miostatina/miostatina latente e suas utilizações
WO2017066561A2 (en) 2015-10-16 2017-04-20 President And Fellows Of Harvard College Regulatory t cell pd-1 modulation for regulating t cell effector immune responses
CA3002676A1 (en) 2015-10-29 2017-05-04 Dana-Farber Cancer Institute, Inc. Methods for identification, assessment, prevention, and treatment of metabolic disorders using pm20d1 and n-lipidated amino acids
EP3374391B1 (de) 2015-11-10 2024-04-17 Visterra, Inc. Antikörpermolekülarzneimittelkonjugate die an lipopolysaccharide binden und verwendungen davon
WO2017091683A1 (en) 2015-11-25 2017-06-01 Visterra, Inc. Antibody molecules to april and uses thereof
JP2019502695A (ja) 2015-12-17 2019-01-31 ノバルティス アーゲー ＰＤ−１に対する抗体分子とＣ−Ｍｅｔ阻害剤との組合せおよびその使用
CN108495651A (zh) 2015-12-17 2018-09-04 诺华股份有限公司 抗pd-1的抗体分子及其用途
SG11201805709RA (en) 2016-01-08 2018-07-30 Scholar Rock Inc Anti-pro/latent myostatin antibodies and methods of use thereof
US11725247B2 (en) 2016-02-29 2023-08-15 Foundation Medicine, Inc. Methods of treating cancer
ES2951648T3 (es) 2016-03-11 2023-10-24 Scholar Rock Inc Inmunoglobulinas de unión a Tgfbeta1 y uso de las mismas
WO2017160599A1 (en) 2016-03-14 2017-09-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of cd300b antagonists to treat sepsis and septic shock
WO2017158436A1 (en) 2016-03-17 2017-09-21 Oslo Universitetssykehus Hf Fusion proteins targeting tumour associated macrophages for treating cancer
AU2017238172A1 (en) 2016-03-21 2018-09-13 Marengo Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
US20170274076A1 (en) 2016-03-25 2017-09-28 Visterra, Inc. Formulations of antibody molecules to dengue virus
CN116333140A (zh) 2016-04-08 2023-06-27 埃缇健康公司D/B/A泽尔拜尔 网蛋白-1结合抗体及其用途
WO2017181098A2 (en) 2016-04-15 2017-10-19 Visterra, Inc. Antibody molecules to zika virus and uses thereof
MA45491A (fr) 2016-06-27 2019-05-01 Juno Therapeutics Inc Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés
CA3028002A1 (en) 2016-06-27 2018-01-04 Juno Therapeutics, Inc. Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
MX2019000327A (es) 2016-07-13 2019-04-11 Biogen Ma Inc Regímenes de dosificación de antagonistas de lingo-1 y usos para el tratamiento de trastornos desmielinizantes.
CA3030837A1 (en) 2016-07-15 2018-01-18 Novartis Ag Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
MA45715A (fr) 2016-07-25 2019-05-29 Biogen Ma Inc Anticorps anti-hspa5 (grp78) et leurs utilisations
JP7148493B2 (ja) 2016-08-01 2022-10-05 ゾーマ （ユーエス） リミテッド ライアビリティ カンパニー 副甲状腺ホルモン受容体１（ｐｔｈ１ｒ）抗体およびその使用
CN110072887A (zh) 2016-08-02 2019-07-30 威特拉公司 工程化多肽及其应用
EP3494141A4 (de) 2016-08-03 2020-04-08 Bio-Techne Corporation Identifizierung von vsig3/vista als ein neuartiger immuncheckpoint und verwendung davon zur immuntherapie
WO2018057955A1 (en) 2016-09-23 2018-03-29 Elstar Therapeutics, Inc. Multispecific antibody molecules comprising lambda and kappa light chains
US10858428B2 (en) 2016-09-28 2020-12-08 Xoma (Us) Llc Antibodies that bind interleukin-2 and uses thereof
EP3519824A1 (de) 2016-10-03 2019-08-07 Abbott Laboratories Verbesserte verfahren zur beurteilung des uch-l1-status in patientenproben
EP3523331A1 (de) 2016-10-07 2019-08-14 Novartis AG Chimäre antigenrezeptoren zur behandlung von krebs
WO2018071576A1 (en) 2016-10-14 2018-04-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Treatment of tumors by inhibition of cd300f
WO2018075408A1 (en) 2016-10-17 2018-04-26 Alexion Pharmaceuticals, Inc. Methods of treating acute myeloid leukemia (aml) with combinations of anti-cd200 antibodies, cytarabine, and daunorubicin
WO2018102594A1 (en) 2016-12-01 2018-06-07 Alexion Pharmaceuticals, Inc. Methods of treating solid tumors with anti-cd200 antibodies
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
JP7360324B2 (ja) 2016-12-23 2023-10-12 ビステラ， インコーポレイテッド 結合ポリペプチドおよびそれを作製する方法
US11155611B2 (en) 2017-01-06 2021-10-26 Scholar Rock, Inc. Compositions and methods for making and using anti-myostatin antibodies
US20180207267A1 (en) 2017-01-06 2018-07-26 Scholar Rock, Inc. Isoform-specific, context-permissive tgfb1 inhibitors and use thereof
WO2018129395A1 (en) 2017-01-06 2018-07-12 Scholar Rock, Inc. Methods for treating metabolic diseases by inhibiting myostatin activation
WO2018130660A1 (en) 2017-01-13 2018-07-19 Academia Sinica Reloadable hydrogel system for treating myocardial infarction
US11382983B2 (en) 2017-01-13 2022-07-12 Academia Sinica Reloadable hydrogel system for treating brain conditions
CN110431150A (zh) 2017-01-18 2019-11-08 威特拉公司 抗体分子-药物偶联物及其用途
US10240205B2 (en) 2017-02-03 2019-03-26 Population Bio, Inc. Methods for assessing risk of developing a viral disease using a genetic test
US11623945B2 (en) 2017-02-06 2023-04-11 The United States Of America, As Represented By The Secretary Of Agriculture Immunostimulating compositions and uses therefore
WO2018151820A1 (en) 2017-02-16 2018-08-23 Elstar Therapeutics, Inc. Multifunctional molecules comprising a trimeric ligand and uses thereof
JP7116736B2 (ja) 2017-03-02 2022-08-10 ノバルティス アーゲー 操作されたヘテロ二量体タンパク質
WO2018169976A1 (en) * 2017-03-13 2018-09-20 Duke University Antigen display system and methods for characterizing antibody responses
JP7346300B2 (ja) 2017-03-23 2023-09-19 アボット・ラボラトリーズ 早期バイオマーカーであるユビキチンカルボキシ末端ヒドロラーゼｌ１を使用する、ヒト対象における外傷性脳損傷の程度の診断及び決定の一助となるための方法
WO2018176019A1 (en) 2017-03-24 2018-09-27 The Regents Of The University Of California Proteoglycan irregularities in abnormal fibroblasts and therapies based therefrom
KR20200020662A (ko) 2017-04-03 2020-02-26 온콜로지, 인크. 면역-종양학 제제와 함께 ps-표적화 항체를 사용하여 암을 치료하는 방법
CA3059542A1 (en) 2017-04-12 2018-10-18 Pfizer Inc. Antibodies having conditional affinity and methods of use thereof
JP7344797B2 (ja) 2017-04-15 2023-09-14 アボット・ラボラトリーズ 早期バイオマーカーを使用する、ヒト対象における外傷性脳損傷の、超急性の診断及び決定の一助となるための方法
WO2018195283A1 (en) 2017-04-19 2018-10-25 Elstar Therapeutics, Inc. Multispecific molecules and uses thereof
CN110603449A (zh) 2017-04-28 2019-12-20 雅培实验室 用同一人受试者的至少两种样品的早期生物标记物帮助超急性诊断确定创伤性脑损伤的方法
WO2018201047A1 (en) 2017-04-28 2018-11-01 Elstar Therapeutics, Inc. Multispecific molecules comprising a non-immunoglobulin heterodimerization domain and uses thereof
US10865238B1 (en) 2017-05-05 2020-12-15 Duke University Complement factor H antibodies
CA3063344A1 (en) 2017-05-23 2018-11-29 Helmholtz Zentrum Munchen - Deutsches Forschungszentrum Fur Gesundheit Und Umwelt (Gmbh) Novel cd73 antibody, preparation and uses thereof
WO2018218169A1 (en) 2017-05-25 2018-11-29 Abbott Laboratories Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers
US10849548B2 (en) 2017-05-30 2020-12-01 Abbott Laboratories Methods for aiding in diagnosing and evaluating a mild traumatic brain injury in a human subject using cardiac troponin I and early biomarkers
EP3630836A1 (de) 2017-05-31 2020-04-08 Elstar Therapeutics, Inc. Multispezifische moleküle, die an myeloproliferatives leukämie (mlp)-protein binden, und deren verwendungen
WO2018226336A1 (en) 2017-06-09 2018-12-13 Providence Health & Services - Oregon Utilization of cd39 and cd103 for identification of human tumor reactive cells for treatment of cancer
EP3642240A1 (de) 2017-06-22 2020-04-29 Novartis AG Antikörpermoleküle gegen cd73 und verwendungen davon
EP3645042A4 (de) 2017-06-26 2021-03-17 Bio-Techne Corporation Hybridom-klone, monoklonale antikörper gegen vsig-4 und verfahren zur herstellung und verwendung
WO2019006007A1 (en) 2017-06-27 2019-01-03 Novartis Ag POSOLOGICAL REGIMES FOR ANTI-TIM3 ANTIBODIES AND USES THEREOF
WO2019010131A1 (en) 2017-07-03 2019-01-10 Abbott Laboratories IMPROVED METHODS FOR MEASURING CARBOXY TERMINATION HYDROLASE LEVELS OF UBIQUITIN L1 IN BLOOD
US11447809B2 (en) 2017-07-06 2022-09-20 President And Fellows Of Harvard College Evolution of tRNA synthetases
CR20200076A (es) 2017-07-14 2020-06-10 Pfizer ANTICUERPOS CONTRA MAdCAM
EP3431496A1 (de) 2017-07-19 2019-01-23 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Anti-isoasp7-amyloid-beta-antikörper und verwendungen davon
CA3070095A1 (en) 2017-07-20 2019-01-24 Novartis Ag Dosage regimens of anti-lag-3 antibodies and uses thereof
MA49690A (fr) 2017-07-28 2021-05-19 Scholar Rock Inc Inhibiteurs spécifiques du complexe ltbp de tgf-bêta 1 et leurs utilisations
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
US11624130B2 (en) 2017-09-18 2023-04-11 President And Fellows Of Harvard College Continuous evolution for stabilized proteins
US11761963B2 (en) 2017-09-27 2023-09-19 Alexion Pharmaceuticals, Inc. Biomarker signature for predicting tumor response to anti-CD200 therapy
KR20200058540A (ko) 2017-10-02 2020-05-27 비스테라, 인크. Cd138에 대한 항체 분자 및 이의 용도
EP3461841B1 (de) 2017-10-02 2019-09-11 Certest Biotec, S.L. Antikörper gegen dps und testvorrichtungen zum nachweis von bakterien der gattung campylobacter
WO2019070161A2 (en) 2017-10-04 2019-04-11 Opko Pharmaceuticals, Llc ARTICLES AND METHODS FOR PERSONALIZED THERAPY OF CANCER
CN111655725A (zh) 2017-10-19 2020-09-11 德比奥药物国际股份有限公司 用于治疗癌症的组合产品
EP3697809A1 (de) 2017-10-20 2020-08-26 Institut Curie Für rush angepasste dap10/12-basierte cars
AU2018368731A1 (en) 2017-11-16 2020-05-14 Novartis Ag Combination therapies
EP3720881A1 (de) 2017-12-08 2020-10-14 Elstar Therapeutics, Inc. Multispezifische moleküle und verwendungen davon
JP7379165B2 (ja) 2017-12-09 2023-11-14 アボット・ラボラトリーズ Ｇｆａｐとｕｃｈ－ｌ１との組合せを使用する、ヒト対象における外傷性脳損傷を診断及び査定する一助となるための方法
CA3067057A1 (en) 2017-12-09 2019-06-13 Abbott Laboratories Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (tbi), using glial fibrillary acidic protein (gfap) and/or ubiquitin carboxy-terminal hydrolase l1 (uch-l1)
WO2019126133A1 (en) 2017-12-20 2019-06-27 Alexion Pharmaceuticals, Inc. Liquid formulations of anti-cd200 antibodies
US11802154B2 (en) 2017-12-20 2023-10-31 Alexion Pharmaceuticals, Inc. Humanized anti-CD200 antibodies and uses thereof
US11787857B2 (en) 2018-02-02 2023-10-17 Bio-Techne Corporation Compounds that modulate the interaction of VISTA and VSIG3 and methods of making and using
EP3765499A1 (de) 2018-03-12 2021-01-20 Zoetis Services LLC Anti-ngf-antikörper und verfahren dafür
EP3765516A2 (de) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunktionale moleküle und verwendungen davon
US20210238280A1 (en) 2018-03-14 2021-08-05 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
WO2019180272A1 (en) 2018-03-23 2019-09-26 Fundación Instituto De Investigación Sanitaria De Santiago De Compostela Anti-leptin affinity reagents for use in the treatment of obesity and other leptin-resistance associated diseases
FI3775909T3 (fi) 2018-03-26 2023-08-01 Glycanostics S R O Välineitä ja menetelmiä proteiinin glykoprofiloimiseksi
EP3775900A1 (de) 2018-03-26 2021-02-17 Alexion Pharmaceuticals, Inc. Hochdurchsatzverfahren zur messung der proteaseaktivität von komplement-c3-konvertase
US20210147547A1 (en) 2018-04-13 2021-05-20 Novartis Ag Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
UY38247A (es) 2018-05-30 2019-12-31 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
WO2019241649A1 (en) 2018-06-14 2019-12-19 President And Fellows Of Harvard College Evolution of cytidine deaminases
WO2019246293A2 (en) 2018-06-19 2019-12-26 Atarga, Llc Antibody molecules to complement component 5 and uses thereof
ES2966050T3 (es) * 2018-06-20 2024-04-18 Hofseth Biocare Asa Hidrolizado de proteínas de pescado en polvo y composición que comprende dicho polvo para su uso como medicamento
DE202019005887U1 (de) 2018-07-03 2023-06-14 Marengo Therapeutics, Inc. Anti-TCR-Antikörpermoleküle und Verwendungen davon
WO2020008083A1 (es) 2018-07-05 2020-01-09 Consejo Superior De Investigaciones Científicas Diana terapéutica en receptores de quimiocinas para la selección de compuestos útiles para el tratamiento de procesos patológicos que implican la señalización de quimiocinas
US20210122814A1 (en) 2018-07-11 2021-04-29 Scholar Rock, Inc. HIGH-AFFINITY, ISOFORM-SELECTIVE TGFß1 INHIBITORS AND USE THEREOF
SI3677278T1 (sl) 2018-07-11 2022-01-31 Scholar Rock, Inc. Izoformno selektivni zaviralci TGFBETA1 in uporaba le-teh
TW202019957A (zh) 2018-07-11 2020-06-01 美商供石公司 TGFβ1抑制劑及其用途
WO2020021465A1 (en) 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) S.R.L. Method of treatment of neuroendocrine tumors
WO2020033700A1 (en) 2018-08-08 2020-02-13 Pml Screening, Llc Mathods for assessing the risk of developing progressive multifocal leukoencephalopathy caused by john cunningham virus by genetic testing
US20220242957A1 (en) 2018-09-27 2022-08-04 Marengo Therapeutics, Inc. Csf1r/ccr2 multispecific antibodies
CA3113818A1 (en) 2018-10-05 2020-04-09 Bavarian Nordic A/S Combination therapy for treating cancer with an intravenous administration of a recombinant mva and an immune checkpoint antagonist or agonist
UY38407A (es) 2018-10-15 2020-05-29 Novartis Ag Anticuerpos estabilizadores de trem2
EP3870286A1 (de) 2018-10-23 2021-09-01 Scholar Rock, Inc. Rgmc-selektive inhibitoren und ihre verwendung
WO2020086408A1 (en) 2018-10-26 2020-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A high-yield perfusion-based transient gene expression bioprocess
BR112021009856A8 (pt) 2018-11-20 2021-09-08 Bavarian Nordic As Terapia para tratamento do câncer com uma administração intratumoral e / ou intravenosa de um mva recombinante que codifica 4-1bbl (cd137l) e / ou cd40l
US20220098310A1 (en) 2018-12-06 2022-03-31 Alexion Pharmaceuticals, Inc. Anti-alk2 antibodies and uses thereof
EP3898686A1 (de) 2018-12-20 2021-10-27 Novartis AG Pharmazeutische kombinationen
EA202192130A1 (ru) 2019-01-30 2021-12-28 Сколар Рок, Инк. Специфичные к ltbp-комплексу ингибиторы tgf и их применение
US11738050B2 (en) 2019-02-01 2023-08-29 Regents Of The University Of Minnesota Compounds binding to fibroblast activation protein alpha
EP3693063A1 (de) 2019-02-06 2020-08-12 Diaccurate Verfahren und zusammensetzungen zur behandlung von krebs
EP3696191A1 (de) 2019-02-14 2020-08-19 Fundación Instituto de Investigación contra la Leucemia Josep Carreras (IJC) Car-t-zellen zur behandlung von cd1a-positivem krebs
US10871640B2 (en) 2019-02-15 2020-12-22 Perkinelmer Cellular Technologies Germany Gmbh Methods and systems for automated imaging of three-dimensional objects
JP2022521937A (ja) 2019-02-21 2022-04-13 マレンゴ・セラピューティクス，インコーポレーテッド ＮＫｐ３０に結合する抗体分子およびその使用
JP2022521750A (ja) 2019-02-21 2022-04-12 マレンゴ・セラピューティクス，インコーポレーテッド カルレティキュリンに結合する多機能性分子およびその使用
CN114026122A (zh) 2019-02-21 2022-02-08 马伦戈治疗公司 结合t细胞相关癌细胞的多功能分子及其用途
CA3130628A1 (en) 2019-02-21 2020-08-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders
CN114126714A (zh) 2019-02-21 2022-03-01 马伦戈治疗公司 抗tcr抗体分子及其用途
MX2021011830A (es) 2019-03-29 2022-01-24 Atarga Llc Anticuerpo anti fgf23.
WO2020257289A2 (en) 2019-06-17 2020-12-24 Visterra, Inc. Humanized antibody molecules to cd138 and uses thereof
EP4004025A1 (de) 2019-07-26 2022-06-01 Visterra, Inc. Interleukin-2-wirkstoffe und verwendungen davon
SI4007777T1 (sl) 2019-08-02 2024-03-29 Fundacio De Recerca Clinic Barcelona-Institut D'investigacions Biomediques August Pi I Sunyer (Frcb-Idibaps) Cart-t celice proti bcma za zdravljenje multiplega mieloma
EP4031658A1 (de) 2019-08-07 2022-07-27 DB Biotech, AS Verbesserte meerrettichperoxidase-polypeptide
US20220332799A1 (en) 2019-09-04 2022-10-20 Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V. (Dzne) Herv inhibitors for use in treating tauopathies
JP2022548881A (ja) 2019-09-18 2022-11-22 ノバルティス アーゲー Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
TW202124446A (zh) 2019-09-18 2021-07-01 瑞士商諾華公司 與ｅｎｔｐｄ２抗體之組合療法
TW202128166A (zh) 2019-10-21 2021-08-01 瑞士商諾華公司 組合療法
EP4048285A1 (de) 2019-10-21 2022-08-31 Novartis AG Tim-3-inhibitoren und verwendungen davon
EP4061406A1 (de) 2019-11-20 2022-09-28 Bavarian Nordic A/S Rekombinante mva-viren zur intratumoralen und/oder intravenösen verabreichung zur behandlung von krebs
CA3165399A1 (en) 2019-12-20 2021-06-24 Novartis Ag Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
EP4084821A4 (de) 2020-01-03 2024-04-24 Marengo Therapeutics Inc An cd33 bindende multifunktionsmoleküle und ihre verwendungen
BR112022013733A2 (pt) 2020-01-11 2022-11-01 Scholar Rock Inc Inibidores de tgfbeta e uso dos mesmos
US20230050148A1 (en) 2020-01-11 2023-02-16 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
TW202140553A (zh) 2020-01-13 2021-11-01 美商威特拉公司 C5ar1抗體分子及其用途
BR112022012310A2 (pt) 2020-01-17 2022-09-06 Novartis Ag Combinação compreendendo um inibidor de tim-3 e um agente hipometilante para uso no tratamento de síndrome mielodisplásica ou leucemia mielomonocítica crônica
EP4100435A1 (de) 2020-02-05 2022-12-14 Larimar Therapeutics, Inc. Tat-peptidbindende proteine und ihre verwendungen
MX2022011289A (es) 2020-03-11 2022-12-08 Fundacio Inst De Recerca Contra La Leucemia Josep Carreras Porcion de direccionamiento a cd22 para el tratamiento de leucemia linfoblastica aguda de celulas b (b-all).
WO2021203024A1 (en) 2020-04-03 2021-10-07 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof
CA3175523A1 (en) 2020-04-13 2021-10-21 Antti Virtanen Methods, complexes and kits for detecting or determining an amount of a .beta.-coronavirus antibody in a sample
EP4139363A1 (de) 2020-04-24 2023-03-01 Marengo Therapeutics, Inc. An t-zellen-verwandte krebszellen bindende multifunktionelle moleküle und verwendungen davon
US20230167193A1 (en) 2020-05-01 2023-06-01 Novartis Ag Immunoglobulin variants
EP4143236A1 (de) 2020-05-01 2023-03-08 Novartis AG Manipulierte immunglobuline
WO2021239666A1 (en) 2020-05-26 2021-12-02 Diaccurate Therapeutic methods
CN115803062A (zh) 2020-06-03 2023-03-14 博泰康医药公司 滋养层细胞表面抗原2(trop-2)抗体
EP4172206A1 (de) 2020-06-24 2023-05-03 Visterra, Inc. Antikörpermoleküle gegen april und verwendungen davon
US20230256114A1 (en) 2020-07-07 2023-08-17 Bionecure Therapeutics, Inc. Novel maytansinoids as adc payloads and their use for the treatment of cancer
WO2022026592A2 (en) 2020-07-28 2022-02-03 Celltas Bio, Inc. Antibody molecules to coronavirus and uses thereof
KR20230042301A (ko) 2020-08-04 2023-03-28 애벗트 라보라토리이즈 샘플에서 sars-cov-2 단백질을 검출하기 위한 개선된 방법 및 키트
KR20230074144A (ko) 2020-08-26 2023-05-26 마렝고 테라퓨틱스, 인크. NKp30에 결합하는 항체 분자 및 이의 용도
AU2021331075A1 (en) 2020-08-26 2023-04-06 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
EP4204458A1 (de) 2020-08-26 2023-07-05 Marengo Therapeutics, Inc. Verfahren zum nachweis von trbc1 oder trbc2
US20230321285A1 (en) 2020-08-31 2023-10-12 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
US20230338587A1 (en) 2020-08-31 2023-10-26 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
AU2021360782A1 (en) 2020-10-14 2023-06-08 Five Prime Therapeutics, Inc. Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
US20230408517A1 (en) 2020-11-24 2023-12-21 Bio-Techne Corporation Anti-severe acute respiratory syndrome coronavirus antibodies
WO2023102384A1 (en) 2021-11-30 2023-06-08 Abbott Laboratories Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
WO2022119841A1 (en) 2020-12-01 2022-06-09 Abbott Laboratories Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
EP4255466A1 (de) 2020-12-04 2023-10-11 Visterra, Inc. Verfahren zur verwendung von interleukin-2-wirkstoffen
CA3202339A1 (en) 2020-12-18 2022-06-23 Mei Jang Protein compositions and methods for producing and using the same
WO2022147147A1 (en) 2020-12-30 2022-07-07 Abbott Laboratories Methods for determining sars-cov-2 antigen and anti-sars-cov-2 antibody in a sample
US20220226442A1 (en) 2021-01-20 2022-07-21 Visterra, Inc. Interleukin-2 agents and uses thereof
EP4284510A1 (de) 2021-01-29 2023-12-06 Novartis AG Dosierungsschemata für anti-cd73- und anti-enpd2-antikörper und verwendungen davon
WO2022182872A2 (en) 2021-02-24 2022-09-01 Alladapt Immunotherapeutics, Inc. Compositions and methods for identification of cross-reactive allergenic proteins and treatment of allergies
AU2022230408A1 (en) 2021-03-03 2023-09-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services La protien as a novel regulator of osteoclastogenesis
WO2022195551A1 (en) 2021-03-18 2022-09-22 Novartis Ag Biomarkers for cancer and methods of use thereof
WO2022204581A2 (en) 2021-03-26 2022-09-29 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
WO2022216993A2 (en) 2021-04-08 2022-10-13 Marengo Therapeutics, Inc. Multifuntional molecules binding to tcr and uses thereof
WO2022235929A1 (en) 2021-05-05 2022-11-10 Radius Pharmaceuticals, Inc. Animal model having homologous recombination of mouse pth1 receptor
AU2022279156A1 (en) 2021-05-18 2023-11-02 Abbott Laboratories Methods of evaluating brain injury in a pediatric subject
WO2022256723A2 (en) 2021-06-03 2022-12-08 Scholar Rock, Inc. Tgf-beta inhibitors and therapeutic use thereof
CA3218590A1 (en) 2021-06-07 2022-12-15 Providence Health & Services - Oregon Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use
WO2022261183A2 (en) 2021-06-08 2022-12-15 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
BR112023026199A2 (pt) 2021-06-14 2024-03-05 Abbott Lab Métodos para diagnosticar ou auxiliar no diagnóstico de lesão cerebral causada por energia acústica, energia eletromagnética, onda de sobrepressurização e/ou rajada de vento
CN113403690B (zh) * 2021-06-21 2022-07-19 吉林大学 一种dna编码化合物库药物分子垂钓方法
IL309078A (en) 2021-06-23 2024-02-01 Scholar Rock Inc A myostatin pathway inhibitor in combination with a GLP-1 pathway activator for use in the treatment of metabolic disorders
IL309957A (en) 2021-07-14 2024-03-01 2Seventy Bio Inc Transgenic T cell receptors attached to antibody binding sites
AU2022328390A1 (en) 2021-08-10 2024-03-21 Adimab, Llc Anti-gdf15 antibodies, compositions and uses thereof
AU2022335718A1 (en) 2021-08-26 2024-03-28 Glycanostics S.R.O Glycoprotein biomarkers for diagnosing cancer
AU2022339759A1 (en) 2021-08-31 2024-03-07 Abbott Laboratories Methods and systems of diagnosing brain injury
AU2022346688A1 (en) 2021-09-14 2024-04-04 Glycanostics S.R.O Use of lectins to determine mammaglobin-a glycoforms in breast cancer
WO2023044483A2 (en) 2021-09-20 2023-03-23 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
CA3232420A1 (en) 2021-09-20 2023-03-23 Alnylam Pharmaceuticals, Inc. Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof
CA3232176A1 (en) 2021-09-30 2023-04-06 Beth MCQUISTON Methods and systems of diagnosing brain injury
CA3235627A1 (en) 2021-10-18 2023-04-27 Byomass Inc. Anti-activin a antibodies, compositions and uses thereof
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
WO2023097254A1 (en) 2021-11-24 2023-06-01 Visterra, Inc. Engineered antibody molecules to cd138 and uses thereof
WO2023097119A2 (en) 2021-11-29 2023-06-01 Dana-Farber Cancer Institute, Inc. Methods and compositions to modulate riok2
WO2023102463A1 (en) 2021-12-01 2023-06-08 Visterra, Inc. Methods of using interleukin-2 agents
WO2023114978A1 (en) 2021-12-17 2023-06-22 Abbott Laboratories Systems and methods for determining uch-l1, gfap, and other biomarkers in blood samples
WO2023122213A1 (en) 2021-12-22 2023-06-29 Byomass Inc. Targeting gdf15-gfral pathway cross-reference to related applications
WO2023118508A1 (en) 2021-12-23 2023-06-29 Bavarian Nordic A/S Recombinant mva viruses for intraperitoneal administration for treating cancer
WO2023129942A1 (en) 2021-12-28 2023-07-06 Abbott Laboratories Use of biomarkers to determine sub-acute traumatic brain injury (tbi) in a subject having received a head computerized tomography (ct) scan that is negative for a tbi or no head ct scan
WO2023147107A1 (en) 2022-01-31 2023-08-03 Byomass Inc. Myeloproliferative conditions
WO2023150652A1 (en) 2022-02-04 2023-08-10 Abbott Laboratories Lateral flow methods, assays, and devices for detecting the presence or measuring the amount of ubiquitin carboxy-terminal hydrolase l1 and/or glial fibrillary acidic protein in a sample
TW202342548A (zh) 2022-02-07 2023-11-01 美商威特拉公司 抗獨特型(anti-idiotype)抗體分子及其用途
US20240092921A1 (en) 2022-04-25 2024-03-21 Visterra, Inc. Antibody molecules to april and uses thereof
WO2023220695A2 (en) 2022-05-13 2023-11-16 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
EP4296279A1 (de) 2022-06-23 2023-12-27 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Anti-transthyretin(ttr)-bindende proteine und ihre verwendungen
WO2024006876A1 (en) 2022-06-29 2024-01-04 Abbott Laboratories Magnetic point-of-care systems and assays for determining gfap in biological samples
WO2024030976A2 (en) 2022-08-03 2024-02-08 Voyager Therapeutics, Inc. Compositions and methods for crossing the blood brain barrier
WO2024059708A1 (en) 2022-09-15 2024-03-21 Abbott Laboratories Biomarkers and methods for differentiating between mild and supermild traumatic brain injury
WO2024062038A1 (en) 2022-09-21 2024-03-28 Elthera Ag Novel binding molecules binding to l1cam

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS53133684A (en) 1977-04-26 1978-11-21 Noda Sangyo Kagaku Kenkyusho Novel bacteriophage and fabricating same
DE2814039C3 (de) 1978-03-31 1981-02-19 Gesellschaft Fuer Biotechnologische Forschung Mbh (Gbf), 3300 Braunschweig Verfahren zur Herstellung von Hybrid-Bakterien
US4411994A (en) 1978-06-08 1983-10-25 The President And Fellows Of Harvard College Protein synthesis
JPS5558096A (en) 1978-10-25 1980-04-30 Noda Sangyo Kagaku Kenkyusho Method of making novel recombined dna
JPS5561798A (en) 1978-10-30 1980-05-09 Noda Sangyo Kagaku Kenkyusho Preparation of novel recombination dna
US4528266A (en) 1979-10-01 1985-07-09 George Pieczenik Method of inserting unique DNA sequences into DNA vectors
US4359535A (en) 1979-10-01 1982-11-16 George Pieczenik Autonomously replicating DNA containing inserted DNA sequences
US4769326A (en) 1980-02-29 1988-09-06 The Regents Of The University Of California Expression linkers
US4338397A (en) 1980-04-11 1982-07-06 President And Fellows Of Harvard College Mature protein synthesis
DE3126021A1 (de) * 1981-07-02 1983-07-28 Basf Ag, 6700 Ludwigshafen Verfahren zur herstellung optisch reiner d- oder l-milchsaeure
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4593002A (en) 1982-01-11 1986-06-03 Salk Institute Biotechnology/Industrial Associates, Inc. Viruses with recombinant surface proteins
EP0088994B1 (de) 1982-03-15 1991-06-19 Schering Corporation Hybride DNS, damit hergestellte Bindungszusammensetzung und Verfahren dafür
US4508826A (en) 1982-04-15 1985-04-02 Merck & Co., Inc. Bacteriophage DNA cloning vector TG1 and microorganisms containing TG1
US4595658A (en) 1982-09-13 1986-06-17 The Rockefeller University Method for facilitating externalization of proteins synthesized in bacteria
US4757013A (en) 1983-07-25 1988-07-12 The Research Foundation Of State University Of New York Cloning vehicles for polypeptide expression in microbial hosts
AU560584B2 (en) 1983-07-28 1987-04-09 Bayer Aktiengesellschaft Homologues of aprotinin
DE3485850T2 (de) 1983-11-08 1993-01-21 Teijin Ltd Genfragmente, abgeleitet vom menschlichen immunoglobulin-gen.
US4703004A (en) 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
US4797363A (en) 1984-03-19 1989-01-10 Board Of Trustees, University Of Illinois Bacteriophages as recognition and identification agents
JPS61104788A (ja) 1984-10-26 1986-05-23 Teijin Ltd 核酸塩基配列
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4774180A (en) 1986-02-26 1988-09-27 Massachusetts Institute Of Technology Construction and application of polyproteins
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4769327A (en) 1985-03-29 1988-09-06 Biotechnica International, Inc. Secretion vector
GB2183661B (en) 1985-03-30 1989-06-28 Marc Ballivet Method for obtaining dna, rna, peptides, polypeptides or proteins by means of a dna recombinant technique
EP0241487B1 (de) 1985-08-28 1998-04-22 PIECZENIK, George Verfahren und mittel zur sortierung und bestimmung biologischer informationen
US5866363A (en) 1985-08-28 1999-02-02 Pieczenik; George Method and means for sorting and identifying biological information
US4908773A (en) 1987-04-06 1990-03-13 Genex Corporation Computer designed stabilized proteins and method for producing same
GB2188322A (en) 1986-03-26 1987-09-30 Bayer Ag Aprotinin and analogues thereof produced by a recombinant host
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB2188933A (en) 1986-04-10 1987-10-14 Bayer Ag Expression vectors for production of polypeptides, method for enhanced expression of polypeptides, hosts containing the expression vectors, products manufactured thereby
US4829052A (en) 1986-06-11 1989-05-09 Monsanto Company Serine protease inhibitors
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
DE3785186T2 (de) 1986-09-02 1993-07-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1988006601A1 (en) 1987-03-02 1988-09-07 Genex Corporation Gene repressors
ATE114723T1 (de) 1987-03-02 1994-12-15 Enzon Lab Inc Organismus als träger für ''single chain antibody domain (scad)''.
DE286239T1 (de) 1987-03-10 1994-02-24 New England Biolabs Inc Herstellung und Reinigung eines Proteins, das mit einem Bindungsprotein fusioniert ist.
EP0285123A3 (de) 1987-04-03 1989-02-01 Stabra AG Verfahren zur vollständigen Mutagenese von Nucleinsäuren
DE3724570A1 (de) 1987-06-27 1989-01-05 Bayer Ag Human-aprotinin, dessen lys-rest in position 15 gegen einen anderen protogenen aminosaeurerest ausgetauscht ist
GB2208511A (en) 1987-08-07 1989-04-05 Bayer Ag Variants of bovine pancreatic trypsin inhibitor produced by recombinant dna technology
DK450187D0 (da) 1987-08-28 1987-08-28 Novo Industri As Fremgangsmaade til fremstilling af proteiner
DK225488D0 (da) 1988-04-26 1988-04-26 Novo Industri As Polypeptid
DE3731874A1 (de) * 1987-09-18 1989-03-30 Schering Ag Verfahren zur herstellung von peptiden durch spezifische spaltung von gentechnisch gewonnenen fusionsproteinen mit collagenasen
DK172110B1 (da) 1988-04-15 1997-10-27 Gen Hospital Corp Fremgangsmåde til isolation af mutanter af DNA-sekvenser og anvendelsen heraf til identifikation af celleoverfladeproteiner
US5010175A (en) 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
IL91501A (en) * 1988-09-02 1998-03-10 Dyax Corp Generation of a variegated library of mutant potential binding proteins and screening of said library for proteins with a desired binding activity
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US7413537B2 (en) 1989-09-01 2008-08-19 Dyax Corp. Directed evolution of disulfide-bonded micro-proteins
US5498538A (en) 1990-02-15 1996-03-12 The University Of North Carolina At Chapel Hill Totally synthetic affinity reagents
US5747334A (en) 1990-02-15 1998-05-05 The University Of North Carolina At Chapel Hill Random peptide library
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
DK0600866T3 (da) 1990-06-01 1998-03-09 Chiron Corp Præparater og fremgangsmåder til identifikation af biologisk aktive molekyler
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
GB9015198D0 (en) * 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
AU8740491A (en) 1990-09-28 1992-04-28 Protein Engineering Corporation Proteinaceous anti-dental plaque agents
IL99553A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing oligonucleotides linked to expression elements,a kit for the preparation of vectors useful for the expression of a diverse population of random peptides and methods utilizing the same
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
NZ241119A (en) 1990-12-20 1993-06-25 Ixsys Inc Manipulating nucleic acid to optimize the binding characteristics of the encoded binding protein
EP0573603B1 (de) 1991-03-01 2003-06-25 Dyax Corp. Hemmstoffe für menschliche neutrophile elastase und menschliches kathepsin g
DE69233697T2 (de) 1991-03-01 2008-01-24 Dyax Corp., Cambridge Verfahren zur Entwicklung von bindenden Mikroproteinen
DK0891982T3 (da) 1992-03-06 2007-09-03 Innogenetics Nv HIV-peptider
WO1994011533A1 (en) 1992-11-12 1994-05-26 The Government Of The United States, As Represented By The Secretary, Department Of Health And Human Services METHODS FOR DETERMINING THE PRESENCE OF FUNCTIONAL p53 IN MAMMALIAN CELLS
US5679548A (en) 1993-02-02 1997-10-21 The Scripps Research Institute Methods for producing polypeptide metal binding sites and compositions thereof
US5432155A (en) 1993-06-29 1995-07-11 The Salk Institute For Biological Studies Conotoxins I
WO1995019431A1 (en) 1994-01-18 1995-07-20 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
EP2022856B1 (de) 1994-08-20 2011-09-14 Gendaq Limited Verbesserungen bei oder im Zusammenhang mit Bindeproteinen zur Erkennung von DNA
US5789538A (en) 1995-02-03 1998-08-04 Massachusetts Institute Of Technology Zinc finger proteins with high affinity new DNA binding specificities
US5955582A (en) 1997-09-26 1999-09-21 Beckman Coulter, Inc. Antibody against a 3-aminophenylboronic-glycated protein complex and its use in an immunoassay

Also Published As

Publication number Publication date
EP1820858A1 (de) 2007-08-22
DE69233325D1 (de) 2004-04-22
EP0573611B9 (de) 2004-10-06
AU1545692A (en) 1992-10-06
DK1452599T3 (da) 2010-12-13
EP0573611B1 (de) 2004-03-17
DE69233769D1 (de) 2009-09-24
JP4618570B2 (ja) 2011-01-26
US7893007B2 (en) 2011-02-22
CA2105300C (en) 2008-12-23
DK0573611T3 (da) 2004-07-19
ES2330052T3 (es) 2009-12-03
JP2010183908A (ja) 2010-08-26
JP2004000221A (ja) 2004-01-08
DE69233697T2 (de) 2008-01-24
EP0573611A1 (de) 1993-12-15
JP2003159086A (ja) 2003-06-03
EP1279731A1 (de) 2003-01-29
ATE363532T1 (de) 2007-06-15
CA2105303A1 (en) 1992-09-02
WO1992015679A1 (en) 1992-09-17
EP0575485A1 (de) 1993-12-29
EP1820858B1 (de) 2009-08-12
JP4451611B2 (ja) 2010-04-14
EP1279731B1 (de) 2007-05-30
US20090234101A1 (en) 2009-09-17
AU1578792A (en) 1992-10-06
JPH07501203A (ja) 1995-02-09
DK1279731T3 (da) 2007-09-24
JPH07501923A (ja) 1995-03-02
JP2008260770A (ja) 2008-10-30
ATE439435T1 (de) 2009-08-15
ATE262036T1 (de) 2004-04-15
EP1452599B1 (de) 2010-08-25
ES2287206T3 (es) 2007-12-16
ES2351693T3 (es) 2011-02-09
DE69233325T2 (de) 2005-03-10
JP3447731B2 (ja) 2003-09-16
EP2224001A1 (de) 2010-09-01
JP4146512B2 (ja) 2008-09-10
WO1992015677A1 (en) 1992-09-17
ES2219638T3 (es) 2004-12-01
DK1820858T3 (da) 2009-11-02
EP1452599A1 (de) 2004-09-01
CA2105300A1 (en) 1992-09-02
ATE478949T1 (de) 2010-09-15
DE69233795D1 (de) 2010-10-07

Similar Documents

Publication Publication Date Title
DE69233697D1 (de) Verfahren zur Herstellung bindender Miniproteine
DE69841273D1 (de) Verfahren zur identifikation von bindestellendomänen, die ihre epitopbindefähigkeit beibehalten
EP2025753A3 (de) Phagemid zum Screenen von Antikörpern
ATE282631T1 (de) Sh3-bindender peptide von cortactin und deren verwendung
ATE152918T1 (de) Technetium-99m-markierte peptide zur bilderzeugung
ATE182896T1 (de) Verfahren zur herstellung und auswahl von peptiden mit spezifischen eigenschaften
CA2095633A1 (en) Enrichment method for variant proteins with altered binding properties
EP0801307A3 (de) Zusammensetzung und Verfahren zum Screenen von Arzneimittelbibliotheken
NO913186D0 (no) Fremgangsmaate for anvendelse og syntese av peptider.
WO1998047343A3 (en) Antibodies or binding protein libraries displayed on phage, cells, or other replicatable genetic packages
EP1712623A3 (de) Selektion von Proteinen unter Verwendung von RNA-protein-fusionen
ATE329624T1 (de) Technetium-99m markierte peptide zur bilderzeugung von thrombus
ATE322684T1 (de) Src sh3 bindende peptide und verfahren zu ihrer isolierung und verwendung
DE69126020T2 (de) Methode zur herstellung und prüfung von verwendbaren peptiden
DE69504795D1 (de) Methoden zur synthese und reinigung von peptiden
GR3033242T3 (en) Arylazo chromoionophores.
SE9002213D0 (sv) Albumin binding proteins
AU2001294399A1 (en) Heavy chain libraries
IT1242076B (it) Peptidi idropaticamente complementari a sequenze aminoacidiche note covalentemente legati in maniera non lineare e procedimento per la loro sintesi
Sepetov et al. New approach in constructing and screening peptide libraries
GB2333295A (en) Modified protein G and fragments thereof

Legal Events

Date Code Title Description
8364 No opposition during term of opposition